|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Anastrozole
|
MedKoo Code#: 100060
|
|
Name:
Anastrozole
|
|
CAS#: 120511-73-1
Synonym: US
brand name: Arimidex. Abbreviation: ANAS. Code names: ICI-D1033
ZD-1033. Chemical structure names:
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile).
alpha,alpha,alpha',
alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile.
IUPAC/Chemical name:
2,2'-(5-((1H-1,2,4-triazol-1-yl)methyl)-1,3-phenylene)bis(2-methylpropanenitrile)
|
|
Chemical structure:
|
Theoretical analysis
:
|
|
|
Chemical Formula: C17H19N5
Exact Mass: 293.16405
Molecular Weight: 293.36626
m/z: 293.16405 (100.0%), 294.16740 (18.4%),
294.16108 (1.8%), 295.17076 (1.6%)
Elemental Analysis: C, 69.60; H, 6.53; N,
23.87
|
|
Availability and price
This agent is
available. For quotation, question, and order, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer significant discount
for larger quantity order.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
Anastrazole is a nonsteroidal inhibitor of estrogen synthesis that
resembles paclitaxel in chemical structure. As a third-generation
aromatase inhibitor, anastrozole selectively binds to and reversibly
inhibits aromatase, a cytochrome P-450 enzyme complex found in many
tissues including those of the premenopausal ovary, liver, and
breast; aromatase catalyzes the aromatization of androstenedione and
testosterone into estrone and estradiol, the final step in estrogen
biosynthesis. In estrogen-dependent breast cancers, anastrozole may
inhibit tumor growth. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus)
Anastrozole is an off-white powder with a molecular
weight of 293.4. Anastrozole has moderate aqueous solubility (0.5 mg/mL
at 25°C); solubility is independent of pH in the physiological range.
Anastrozole is freely soluble in methanol, acetone, ethanol, and
tetrahydrofuran, and very soluble in acetonitrile.
Each tablet contains as inactive ingredients: lactose, magnesium
stearate, hydroxypropylmethylcellulose, polyethylene glycol, povidone,
sodium starch glycolate, and titanium dioxide.
The growth of many cancers of the breast is
stimulated or maintained by estrogens. Treatment of breast cancer
thought to be hormonally responsive (i.e., estrogen and/or progesterone
receptor positive or receptor unknown) has included a variety of efforts
to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy)
or inhibit estrogen effects (antiestrogens and progestational agents).
These interventions lead to decreased tumor mass or delayed progression
of tumor growth in some women.
In postmenopausal women, estrogens are mainly derived from the action of
the aromatase enzyme, which converts adrenal androgens (primarily
androstenedione and testosterone) to estrone and estradiol. The
suppression of estrogen biosynthesis in peripheral tissues and in the
cancer tissue itself can therefore be achieved by specifically
inhibiting the aromatase enzyme.
Anastrozole is a potent and selective non-steroidal aromatase inhibitor.
It significantly lowers serum estradiol concentrations and has no
detectable effect on formation of adrenal corticosteroids or aldosterone.
According to
http://en.wikipedia.org/wiki/Anastrozole, Annual sales approx
$2.2bn. Patent expires 2010 in the US[1]; however, the generic form is
available in some other markets.
1: Riemsma R, Forbes CA, Kessels A,
Lykopoulos K, Amonkar MM, Rea DW, Kleijnen J. Systematic review of
aromatase inhibitors in the first-line treatment for hormone sensitive
advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010 Jun
10. [Epub ahead of print] PubMed PMID: 20535542.
2: Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H,
Iwata H,
Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N,
Hisamatsu
K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y. Phase III
randomized adjuvant study of tamoxifen alone versus sequential tamoxifen
and anastrozole in
Japanese postmenopausal women with hormone-responsive breast cancer:
N-SAS BC03 study. Breast Cancer Res Treat. 2010 Jun;121(2):379-87.
PubMed PMID: 20390343.
3: Gradishar WJ. Adjuvant endocrine therapy for early breast cancer: the
story so far. Cancer Invest. 2010 May;28(4):433-42. Review. PubMed PMID:
20307199.
4: Loehberg CR, Jud SM, Haeberle L, Heusinger K, Dilbat G, Hein A, Rauh
C, Dall P, Rix N, Heinrich S, Buchholz S, Lex B, Reichler B, Adamietz B,
Schulz-Wendtland R, Beckmann MW, Fasching PA. Breast cancer risk
assessment in a mammography screening program and participation in the
IBIS-II chemoprevention trial. Breast
Cancer Res Treat. 2010 May;121(1):101-10. Epub 2010 Mar 21. PubMed PMID:
20306293.
5: Sabnis G, Brodie A. Understanding resistance to endocrine agents:
molecular mechanisms and potential for intervention. Clin Breast Cancer.
2010 Feb;10(1):E6-E15. PubMed PMID: 20133251.
6: Janni W, Hepp P. Adjuvant aromatase inhibitor therapy: outcomes and
safety. Cancer Treat Rev. 2010 May;36(3):249-61. Epub 2010 Feb 4.
Review. PubMed PMID: 20133065.
7: Montero AJ, Talebi TN, Zhu Y, Branch KD, Goldsberry GT, Baker MK,
Gluck S. Successful Use of Biweekly Gemcitabine Plus Nab-Paclitaxel in
Two Male Patients With Stage IV Breast Cancer: Case Reports and Review
of the Literature. Am J Ther. 2009 Dec 19. [Epub ahead of print] PubMed
PMID: 20027107.
8: Khosla S. Testosterone: more is not always better. J Clin Endocrinol
Metab. 2009 Dec;94(12):4665-7. PubMed PMID: 19959753.
9: Ghazi M, Roux C. Hormonal deprivation therapy-induced osteoporosis in
postmenopausal women with breast cancer. Best Pract Res Clin Rheumatol.
2009 Dec;23(6):805-11. Review. PubMed PMID: 19945692.
10: van de Velde CJ, Verma S, van Nes JG, Masterman C, Pritchard KI.
Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine
therapy in postmenopausal patients with early breast cancer. Cancer
Treat Rev. 2010 Feb;36(1):54-62. Epub 2009 Nov 26. Review. PubMed PMID:
19944537.
11: Baumann CK, Castiglione-Gertsch M. Clinical use of selective
estrogen receptor modulators and down regulators with the main focus on
breast cancer. Minerva Ginecol. 2009 Dec;61(6):517-39. Review. PubMed
PMID: 19942839.
12: Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D.
Aromatase inhibitors for female infertility: a systematic review of the
literature. Reprod
Biomed Online. 2009 Oct;19(4):456-71. Review. PubMed PMID: 19909585.
13: Geisler J, Lřnning PE. Impact of aromatase inhibitors on bone health
in breast cancer patients. J Steroid Biochem Mol Biol. 2010 Feb
28;118(4-5):294-9. Epub 2009 Oct 13. PubMed PMID: 19833206.
14: Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer
treatment
and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab
Rev. 2010;42(1):176-88. PubMed PMID: 19821643.
15: Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for
treatment of advanced breast cancer in postmenopausal women. Cochrane
Database Syst Rev. 2009 Oct 7;(4):CD003370. Review. PubMed PMID:
19821307.
16: Milani M, Jha G, Potter DA. Anastrozole Use in Early Stage Breast
Cancer of Post-Menopausal Women. Clin Med Ther. 2009 Mar 31;1:141-156.
PubMed PMID: 19794821; PubMed Central PMCID: PMC2753667.
17: Cortes J, Baselga J. How to treat hormone receptor-positive, human
epidermal
growth factor receptor 2-amplified breast cancer. J Clin Oncol. 2009 Nov
20;27(33):5492-4. Epub 2009 Sep 28. PubMed PMID: 19786653.
18: Gangadhara S, Bertelli G. Long-term efficacy and safety of
anastrozole for adjuvant treatment of early breast cancer in
postmenopausal women. Ther Clin Risk Manag. 2009 Aug;5(4):291-300. Epub
2009 May 4. PubMed PMID: 19753124; PubMed Central PMCID: PMC2690973.
19: Glück S. Exemestane as first-line therapy in postmenopausal women
with recurrent or metastatic breast cancer. Am J Clin Oncol. 2010
Jun;33(3):314-9. Review. PubMed PMID: 19730353.
20: Watanabe N, Ootawa Y, Kodama K, Kaide A, Ootsuka N, Matsuoka J.
Concurrent administration of chemo-endocrine therapy for postmenopausal
breast cancer patients. Breast Cancer. 2009 Sep 1. [Epub ahead of print]
PubMed PMID: 19728030.
21: Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S,
Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P.
Clinical perspectives on the utility of aromatase inhibitors for the
adjuvant treatment of breast cancer. Breast. 2009 Aug;18 Suppl 2:S1-11.
Review. PubMed PMID: 19712865.
22: Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant
M, Steger G. Breast cancer chemoprevention - a vision not yet realized.
Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. Epub 2009 Jul 20.
Review. PubMed PMID: 19686352.
23: Keating GM. Letrozole: a review of its use in the treatment of
postmenopausal women with hormone-responsive early breast cancer. Drugs.
2009 Aug 20;69(12):1681-705. doi: 10.2165/10482340-000000000-00000.
Review. PubMed PMID: 19678717.
24: Eckmann KR, Kockler DR. Aromatase inhibitors for ovulation and
pregnancy in polycystic ovary syndrome. Ann Pharmacother. 2009
Jul;43(7):1338-46. Epub 2009 Jul 7. Review. PubMed PMID: 19584394.
25: Vercellini P, Crosignani PG, Somigliana E, Berlanda N, Barbara G,
Fedele L. Medical treatment for rectovaginal endometriosis: what is the
evidence? Hum Reprod. 2009 Oct;24(10):2504-14. Epub 2009 Jul 2. Review.
PubMed PMID: 19574277.
26: Johnston SR. Enhancing the efficacy of hormonal agents with selected
targeted agents. Clin Breast Cancer. 2009 Jun;9 Suppl 1:S28-36. Review.
PubMed PMID: 19561004.
27: Nabholtz JM, Mouret-Reynier MA, Durando X, Van Praagh I, Al-Sukhun
S, Ferriere JP, Chollet P. Comparative review of anastrozole, letrozole
and exemestane in the management of early breast cancer. Expert Opin
Pharmacother. 2009 Jun;10(9):1435-47. Review. PubMed PMID: 19445563.
28: Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of
aromatase:
saga of an important biological mediator and therapeutic target. Endocr
Rev. 2009 Jun;30(4):343-75. Epub 2009 Apr 23. Review. PubMed PMID:
19389994.
29: Schwartzberg LS, Cobb P, Senecal F, Henry D, Kulig K, Walker MS,
Houts AC, Stepanski EJ. Initial treatment and changes in adjuvant
endocrine therapy for early stage breast cancer. Breast. 2009
Apr;18(2):78-83. Epub 2009 Apr 1. PubMed
PMID: 19342237.
30: Untch M, Jackisch C. Exemestane in early breast cancer: a review.
Ther Clin Risk Manag. 2008 Dec;4(6):1295-304. PubMed PMID: 19337436;
PubMed Central PMCID:
PMC2643110.
31: Azria D, Jacot W, Gligorov J, Belkacémi Y, Zaman K, Romieu G,
Ozsahin M. [Adjuvant breast cancer treatment with hormono-radiotherapy].
Bull Cancer. 2009 Mar;96(3):285-9. Review. French. PubMed PMID:
19318306.
32: Barry M, Kell MR. Enhancing the adjuvant treatment of hormone
receptor positive breast cancer. Breast J. 2009 Mar-Apr;15(2):194-8.
PubMed PMID: 19292807.
33: Nothnick WB, Zhang X. Future targets in endometriosis treatment:
targeting the endometriotic implant. Mini Rev Med Chem. 2009
Mar;9(3):324-8. Review. PubMed PMID: 19275725.
34: Dunn BK, Ryan A. Phase 3 trials of aromatase inhibitors for breast
cancer prevention: following in the path of the selective estrogen
receptor modulators.
Ann N Y Acad Sci. 2009 Feb;1155:141-61. Review. PubMed PMID: 19250201.
35: Ewer MS, Glück S. A woman's heart: the impact of adjuvant endocrine
therapy on cardiovascular health. Cancer. 2009 May 1;115(9):1813-26.
Review. PubMed PMID: 19235248.
36: Dunkel L. Update on the role of aromatase inhibitors in growth
disorders. Horm Res. 2009 Jan;71 Suppl 1:57-63. Epub 2009 Jan 21.
Review. PubMed PMID: 19153508.
37: Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U,
Hadji P. Adherence to adjuvant endocrine therapy in postmenopausal women
with breast cancer. Ann Oncol. 2009 Mar;20(3):431-6. Epub 2009 Jan 15.
PubMed PMID: 19150950.
38: Buzdar AU. Fulvestrant--a novel estrogen receptor antagonist for the
treatment of advanced breast cancer. Drugs Today (Barc). 2008
Sep;44(9):679-92. Review. PubMed PMID: 19137123.
39: Abrial C, Durando X, Mouret-Reynier MA, Thivat E, Bayet-Robert M,
Nayl B, Dubray P, Pomel C, Chollet P, Penault-Llorca F. Role of
neo-adjuvant hormonal therapy in the treatment of breast cancer: a
review of clinical trials. Int J Gen Med. 2009 Jul 30;2:129-40. PubMed
PMID: 20360896; PubMed Central PMCID: PMC2840558.
40: Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G. The Coffey
Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
Urol Oncol. 2009 Jan-Feb;27(1):53-63. Review. PubMed PMID: 19111799.
41: Blackwell KL. Are all aromatase inhibitors alike? Breast Cancer Res
Treat. 2008 Dec;112 Suppl 1:35-43. Epub 2008 Dec 20. PubMed PMID:
19101793.
42: Chlebowski RT. Optimizing aromatase inhibitor integration into
initial treatment strategies in postmenopausal women with
hormone-receptor-positive early breast cancer. Breast Cancer Res Treat.
2008 Dec;112 Suppl 1:25-34. Epub 2008 Dec 20. PubMed PMID: 19101792.
43: Cuzick J, Sestak I, Cella D, Fallowfield L; ATAC Trialists' Group.
Treatment-emergent endocrine symptoms and the risk of breast cancer
recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol.
2008 Dec;9(12):1143-8. Epub 2008 Oct 29. PubMed PMID: 18976959.
44: Howell A. The endocrine prevention of breast cancer. Best Pract Res
Clin Endocrinol Metab. 2008 Aug;22(4):615-23. Review. PubMed PMID:
18971122.
45: Yamamoto Y, Iwase H. Safety profiles of aromatase inhibitors and
selective estrogen-receptor modulators in the treatment of early breast
cancer. Int J Clin
Oncol. 2008 Oct;13(5):384-94. Epub 2008 Oct 23. Review. PubMed PMID:
18946748.
46: Balducci L. Treating elderly patients with hormone sensitive breast
cancer: what do the data show? Cancer Treat Rev. 2009 Feb;35(1):47-56.
Epub 2008 Oct 5. Review. PubMed PMID: 18840391.
47: Juraskova I, Butow P, Lopez A, Seccombe M, Coates A, Boyle F,
McCarthy N, Reaby L, Forbes JF. Improving informed consent: pilot of a
decision aid for women invited to participate in a breast cancer
prevention trial (IBIS-II DCIS). Health Expect. 2008 Sep;11(3):252-62.
PubMed PMID: 18816321.
48: Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri
Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
Outcome prediction for estrogen receptor-positive breast cancer based on
postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer
Inst. 2008 Oct 1;100(19):1380-8. Epub 2008 Sep 23. PubMed PMID:
18812550; PubMed Central PMCID: PMC2556704.
49: Iwase H. Current topics and perspectives on the use of aromatase
inhibitors in the treatment of breast cancer. Breast Cancer.
2008;15(4):278-90. Epub 2008 Sep 23. Review. PubMed PMID: 18810576.
50: Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield
LJ. Effects of anastrozole on cognitive performance in postmenopausal
women: a randomised, double-blind chemoprevention trial (IBIS II).
Lancet Oncol. 2008 Oct;9(10):953-61. Epub 2008 Sep 1. PubMed PMID:
18768369.
51: Cuzick J. IBIS II: a breast cancer prevention trial in
postmenopausal women using the aromatase inhibitor anastrozole. Expert
Rev Anticancer Ther. 2008 Sep;8(9):1377-85. PubMed PMID: 18759690.
52: Chlebowski RT. Clinical trial presentations, agency guidelines, and
oncology
practice: findings from the arimidex, tamoxifen, alone or in combination
trial. Clin Breast Cancer. 2008 Aug;8(4):343-6. PubMed PMID: 18757261.
53: Nabholtz JM. Long-term safety of aromatase inhibitors in the
treatment of breast cancer. Ther Clin Risk Manag. 2008 Feb;4(1):189-204.
PubMed PMID: 18728707; PubMed Central PMCID: PMC2503653.
54: Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR,
Buzdar AU; ATAC Trialists' Group. Risk factors for joint symptoms in
patients enrolled in the ATAC trial: a retrospective, exploratory
analysis. Lancet Oncol. 2008 Sep;9(9):866-72. Epub 2008 Aug 12. PubMed
PMID: 18703382.
55: Flemming J, Madarnas Y, Franek JA. Fulvestrant for systemic therapy
of locally advanced or metastatic breast cancer in postmenopausal women:
a systematic review. Breast Cancer Res Treat. 2009 May;115(2):255-68.
Epub 2008 Aug 6. Review. PubMed PMID: 18683044.
56: Aydiner A, Tas F. Meta-analysis of trials comparing anastrozole and
tamoxifen for adjuvant treatment of postmenopausal women with early
breast cancer. Trials.
2008 Jul 29;9:47. PubMed PMID: 18664277; PubMed Central PMCID:
PMC2503952.
57: Nagykálnai T. [Adjuvant endocrine therapy in postmenopausal
hormone-sensitive breast cancer: to start, to switch or to extend?].
Magy Onkol. 2008 Jun;52(2):133-43. Review. Hungarian. PubMed PMID:
18640889.
58: Lřnning PE, Geisler J. Experience with exemestane in the treatment
of early and advanced breast cancer. Expert Opin Drug Metab Toxicol.
2008 Jul;4(7):987-97. Review. PubMed PMID: 18624685.
59: Tang SC. Reducing the risk of distant metastases: a better end point
in adjuvant aromatase inhibitor breast cancer trials? Cancer Invest.
2008 Jun;26(5):481-90. Review. PubMed PMID: 18568770.
60: Lřnning PE. Exploring the lack of cross-resistance between aromatase
inhibitors: evidence for a difference? Anticancer Drugs. 2008 Mar;19
Suppl 2:S11-3. Review. PubMed PMID: 18337640.
61: Sanford M, Plosker GL. Anastrozole: a review of its use in
postmenopausal women with early-stage breast cancer. Drugs.
2008;68(9):1319-40. Review. PubMed PMID: 18547136.
62: Tusquets Trías de Bes I, Tormo SS, Mestres JA. Start strong or
switch? Adjuvant endocrine strategies for postmenopausal women with
hormone-sensitive breast cancer. Biomed Pharmacother. 2009
Jan;63(1):1-10. Epub 2008 May 16. Review. PubMed PMID: 18539426.
63: Colozza M, Califano R, Minenza E, Dinh P, Azambuja E. Aromatase
inhibitors: a new reality for the adjuvant endocrine treatment of
early-stage breast cancer in
postmenopausal women. Mini Rev Med Chem. 2008 Jun;8(6):564-74. Review.
PubMed PMID: 18537711.
64: Doggrell SA. Is long-term adjuvant treatment of breast cancer with
anastrozole indicated? Expert Opin Pharmacother. 2008 Jun;9(9):1619-22.
PubMed PMID: 18518790.
65: Herold CI, Blackwell KL. Aromatase inhibitors for breast cancer:
proven efficacy across the spectrum of disease. Clin Breast Cancer. 2008
Feb;8(1):50-64. Review. PubMed PMID: 18501059.
66: Dixon JM. Reducing early recurrence with adjuvant aromatase
inhibitors: what
is the evidence? Breast. 2008 Aug;17(4):353-60. Epub 2008 May 19.
Review. PubMed
PMID: 18490163.
67: Nabholtz JM, Gligorov J. The emerging role of aromatase inhibitors
in the adjuvant management of breast cancer. Rev Recent Clin Trials.
2006 Sep;1(3):237-49. Review. PubMed PMID: 18473976.
68: Howell A. The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC)
Trial: a
step forward in the treatment of early breast cancer. Rev Recent Clin
Trials. 2006 Sep;1(3):207-15. Review. PubMed PMID: 18473974.
69: Barnadas A, Gil M, Sánchez-Rovira P, Llombart A, Adrover E, Estevez
LG, de la Haba J, Calvo L. Neoadjuvant endocrine therapy for breast
cancer: past, present and future. Anticancer Drugs. 2008
Apr;19(4):339-47. Review. PubMed PMID: 18454044.
70: Khosravi Shahi P, Izarzugaza Perón Y, Encinas García S, Díaz Muńoz
de la Espada VM, Pérez Manga G. [Adjuvant treatment of operable breast
cancer]. An Med
Interna. 2008 Jan;25(1):36-40. Review. Spanish. PubMed PMID: 18377195.
71: Cuzick J. Aromatase inhibitors in early breast-cancer treatment: The
story so far. Breast. 2008 Apr;17 Suppl 3:S2-8. Review. PubMed PMID:
18367396.
72: Nabholtz JM. Aromatase inhibitors in the management of early breast
cancer. Eur J Surg Oncol. 2008 Nov;34(11):1199-207. Epub 2008 Mar 21.
Review. PubMed PMID: 18359182.
73: Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse
events.
Endocr Relat Cancer. 2008 Mar;15(1):73-90. Review. PubMed PMID:
18310277.
74: Carpenter R. Choosing early adjuvant therapy for postmenopausal
women with hormone-sensitive breast cancer: aromatase inhibitors versus
tamoxifen. Eur J Surg Oncol. 2008 Jul;34(7):746-55. Epub 2008 Mar 4.
Review. PubMed PMID: 18296017.
75: Brufsky AM. Managing bone loss in women with early-stage breast
cancer receiving aromatase inhibitors. Clin Breast Cancer. 2007 Dec;8
Suppl 1:S22-34. Review. PubMed PMID: 18282367.
76: Herold CI, Blackwell KL. The impact of adjuvant endocrine therapy on
reducing the risk of distant metastases in hormone-responsive breast
cancer. Breast. 2008
Jan;17 Suppl 1:S15-24. Review. PubMed PMID: 18279763.
77: Geisler J. Aromatase inhibitors: from bench to bedside and back.
Breast Cancer. 2008;15(1):17-26. PubMed PMID: 18224389.
78: Cuzick J. Chemoprevention of breast cancer. Breast Cancer.
2008;15(1):10-6. PubMed PMID: 18224388.
79: Mamounas EP. Facilitating breast-conserving surgery and preventing
recurrence: aromatase inhibitors in the neoadjuvant and adjuvant
settings. Ann Surg Oncol. 2008 Mar;15(3):691-703. Epub 2008 Jan 15.
Review. PubMed PMID: 18196346.
80: Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI.
Aromatase inhibitors in adjuvant therapy for hormone receptor positive
breast cancer: a systematic review. Cancer Treat Rev. 2008
Apr;34(2):157-74. Epub 2007 Dec 31. Review. PubMed PMID: 18164821.
81: Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic
risk in
the treatment of postmenopausal women with early breast cancer. Clin
Interv Aging. 2008;3(4):647-57. Review. PubMed PMID: 19281057; PubMed
Central PMCID: PMC2682397.
82: Prowell TM, Stearns V. Extended adjuvant therapy for breast
cancer--how much
is enough? J Natl Cancer Inst. 2007 Dec 19;99(24):1825-7. Epub 2007 Dec
11. PubMed PMID: 18073372.
83: Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase
inhibitor clinical trials in postmenopausal women with early breast
cancer. Cancer. 2008 Feb 1;112(3 Suppl):700-9. PubMed PMID: 18072256.
84: Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC,
Miller WR,
Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted
manipulation of breast cancer: summary statement for the Sixth Cambridge
Conference. Cancer. 2008 Feb 1;112(3 Suppl):673-8. PubMed PMID:
18072254.
85: Hadji P, Bundred N. Reducing the risk of cancer treatment-associated
bone loss in patients with breast cancer. Semin Oncol. 2007 Dec;34(6
Suppl 4):S4-10. Review. PubMed PMID: 18068489.
86: Sieber PR. Treatment of bicalutamide-induced breast events. Expert
Rev Anticancer Ther. 2007 Dec;7(12):1773-9. Review. PubMed PMID:
18062751.
87: Orman JS, Perry CM. Trastuzumab : in HER2 and hormone receptor
co-positive metastatic breast cancer. Drugs. 2007;67(18):2781-9. Review.
PubMed PMID: 18062723.
88: Gligorov J, Pritchard K, Goss P. Adjuvant and extended adjuvant use
of aromatase inhibitors: reducing the risk of recurrence and distant
metastasis. Breast. 2007 Dec;16 Suppl 3:S1-9. Epub 2007 Dec 3. Review.
PubMed PMID: 18061455.
89: Thürlimann B. Reducing the risk of early recurrence in
hormone-responsive breast cancer. Ann Oncol. 2007 Sep;18 Suppl
8:viii8-17. PubMed PMID: 17890214.
90: Arnedos M, Smith I. Progression of endocrine therapies for breast
cancer: where are we headed? Expert Rev Anticancer Ther. 2007
Nov;7(11):1651-64. Review.
PubMed PMID: 18020931.
91: Perez EA. Safety of aromatase inhibitors in the adjuvant setting.
Breast Cancer Res Treat. 2007;105 Suppl 1:75-89. Epub 2007 Oct 3.
Review. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):379. PubMed
PMID: 17912638; PubMed Central PMCID: PMC2001222.
92: O'Shaughnessy J. A decade of letrozole: FACE. Breast Cancer Res
Treat. 2007;105 Suppl 1:67-74. Epub 2007 Oct 3. Erratum in: Breast
Cancer Res Treat. 2008 Nov;112(2):373. PubMed PMID: 17912637; PubMed
Central PMCID: PMC2001225.
93: Bhatnagar AS. The discovery and mechanism of action of letrozole.
Breast Cancer Res Treat. 2007;105 Suppl 1:7-17. Epub 2007 Oct 3. Review.
Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):385. PubMed PMID:
17912633; PubMed Central PMCID: PMC2001216.
94: Dutta U, Pant K. Aromatase inhibitors: past, present and future in
breast cancer therapy. Med Oncol. 2008;25(2):113-24. Epub 2007 Nov 1.
Review. PubMed PMID: 17973095.
95: Rose C. Increasing protection after tamoxifen: insights from the
extended adjuvant aromatase inhibitor trials. J Cancer Res Clin Oncol.
2008 Jan;134(1):7-17. Epub 2007 Oct 16. Review. PubMed PMID: 17938958.
96: Graham PH. Anastrozole for malignant and benign conditions: present
applications and future therapeutic integrations. Expert Opin
Pharmacother. 2007
Oct;8(14):2347-57. Review. PubMed PMID: 17927488.
97: Jahanzeb M. Reducing the risk for breast cancer recurrence after
completion of tamoxifen treatment in postmenopausal women. Clin Ther.
2007 Aug;29(8):1535-47. Review. PubMed PMID: 17919537.
98: Poole R, Paridaens R. The use of third-generation aromatase
inhibitors and tamoxifen in the adjuvant treatment of postmenopausal
patients with hormone-dependent breast cancer: evidence based review.
Curr Opin Oncol. 2007 Nov;19(6):564-72. Review. PubMed PMID: 17906453.
99: Fabian CJ. The what, why and how of aromatase inhibitors: hormonal
agents for treatment and prevention of breast cancer. Int J Clin Pract.
2007 Dec;61(12):2051-63. Epub 2007 Sep 24. Review. PubMed PMID:
17892469; PubMed Central PMCID: PMC2228389.
100: Del Mastro L, Clavarezza M, Venturini M. Reducing the risk of
distant metastases in breast cancer patients: role of aromatase
inhibitors. Cancer Treat
Rev. 2007 Dec;33(8):681-7. Epub 2007 Sep 11. Review. PubMed PMID:
17850976.
101: Paepke S, Jacobs VR, Ohlinger R, Warm M, Kümmel S, Thomas A,
Harbeck N, Kiechle-Bahat M. Treatment strategies that effectively reduce
early recurrence risk in postmenopausal women with endocrine-sensitive
breast cancer: AIs upfront
vs. switching. J Cancer Res Clin Oncol. 2007 Dec;133(12):905-16. Epub
2007 Sep 6. Review. PubMed PMID: 17805570.
102: Gligorov J, Azria D, Namer M, Khayat D, Spano JP. Novel therapeutic
strategies combining antihormonal and biological targeted therapies in
breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol
Hematol. 2007 Nov;64(2):115-28. Epub 2007 Aug 16. Review. PubMed PMID:
17702596.
103: Rugo HS. The breast cancer continuum in hormone-receptor-positive
breast cancer in postmenopausal women: evolving management options
focusing on aromatase inhibitors. Ann Oncol. 2008 Jan;19(1):16-27. Epub
2007 Aug 9. Review. PubMed PMID: 17693420.
104: Robertson JF. Fulvestrant (Faslodex) -- how to make a good drug
better. Oncologist. 2007 Jul;12(7):774-84. Review. PubMed PMID:
17673609.
105: Winters L, Habin K, Gallagher J. Aromatase inhibitors and
musculoskeletal pain in patients with breast cancer. Clin J Oncol Nurs.
2007 Jun;11(3):433-9. Review. PubMed PMID: 17623627.
106: Chen S, Masri S, Hong Y, Wang X, Phung S, Yuan YC, Wu X. New
experimental models for aromatase inhibitor resistance. J Steroid
Biochem Mol Biol. 2007 Aug-Sep;106(1-5):8-15. Epub 2007 May 24. Review.
PubMed PMID: 17611102; PubMed Central PMCID: PMC2743954.
107: Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal
therapies for early breast cancer: systematic review and economic
evaluation. Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134.
Review. PubMed PMID: 17610808.
108: Karnon J, Delea T, Barghout V. Cost utility analysis of early
adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal
women with early invasive breast cancer: the UK perspective. Eur J
Health Econ. 2008 May;9(2):171-83. Epub 2007 Jun 30. PubMed PMID:
17602251.
109: Fallowfield L. Quality of life issues in relation to the aromatase
inhibitor. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):168-72.
Epub 2007 May 24. PubMed PMID: 17587567.
110: Gralow JR. Bone density in breast cancer: when to intervene? J Clin
Oncol. 2007 Aug 1;25(22):3194-7. Epub 2007 Jun 18. PubMed PMID:
17577014.
111: Bell R, Lewis J. Assessing the risk of bone fracture among
postmenopausal women who are receiving adjuvant hormonal therapy for
breast cancer. Curr Med Res Opin. 2007 May;23(5):1045-51. PubMed PMID:
17519070.
112: Monnier AM. The Breast International Group 1-98 trial: big results
for women with hormone-sensitive early breast cancer. Expert Rev
Anticancer Ther. 2007 May;7(5):627-34. Review. PubMed PMID: 17492927.
113: Macaskill EJ, Dixon JM. Neoadjuvant use of endocrine therapy in
breast cancer. Breast J. 2007 May-Jun;13(3):243-50. Review. PubMed PMID:
17461898.
114: Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ,
Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson
NE, Norton L, Perez EA,
Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of
Canada Clinical Trials Group MA.17. Efficacy of letrozole extended
adjuvant therapy according to estrogen receptor and progesterone
receptor status of the primary tumor: National Cancer Institute of
Canada Clinical Trials Group MA.17. J Clin Oncol. 2007 May
20;25(15):2006-11. Epub 2007 Apr 23. PubMed PMID: 17452676.
115: Yang MT, Lian ZQ. [Advancement in endocrine therapy for breast
cancer]. Ai Zheng. 2007 Apr;26(4):440-4. Review. Chinese. PubMed PMID:
17430670.
116: Akashi-Tanaka S, Omatsu M, Shimizu C, Ando M, Terada K, Shien T,
Kinoshita T, Fujiwara Y, Seki K, Hasegawa T, Fukutomi T. Favorable
outcome in patients with breast cancer in the presence of pathological
response after neoadjuvant endocrine therapy. Breast. 2007
Oct;16(5):482-8. Epub 2007 Apr 5. PubMed PMID: 17418576.
117: Karnon J. Cost-effectiveness of letrozole, anastrozole and
exemestane for early adjuvant breast cancer. Expert Rev Pharmacoecon
Outcomes Res. 2007 Apr;7(2):143-53. PubMed PMID: 20528441.
118: Glück S. The prevention and management of distant metastases in
women with breast cancer. Cancer Invest. 2007 Feb;25(1):6-13. Review.
PubMed PMID: 17364551.
119: van Nes JG, Seynaeve C, van de Velde CJ, Nortier JW. [Optimal
adjuvant hormone therapy in postmenopausal women with hormone-sensitive
mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole,
exemestane and letrozole]. Ned Tijdschr Geneeskd. 2006 Dec
30;150(52):2863-9. Review. Dutch. PubMed PMID: 17319217.
120: Cianfrocca M, Wolff AC. Optimizing endocrine therapy for
premenopausal and postmenopausal women with breast cancer. Oncology
(Williston Park). 2007 Jan;21(1):63-9; discussion 69, 72, 75 passim.
Review. PubMed PMID: 17313157.
121: Howell A, Clarke RB, Evans G, Bundred N, Cuzick J, Santen R, Allred
C. Estrogen deprivation for breast cancer prevention. Recent Results
Cancer Res. 2007;174:151-67. Review. PubMed PMID: 17302193.
122: Boccardo F, Rubagotti A, Aldrighetti D, Buzzi F, Cruciani G, Farris
A, Mustacchi G, Porpiglia M, Schieppati G, Sismondi P. Switching to an
aromatase inhibitor provides mortality benefit in early breast
carcinoma: pooled analysis of 2 consecutive trials. Cancer. 2007 Mar
15;109(6):1060-7. PubMed PMID: 17295293.
123: Untch M, Jackisch C. Optimal treatment strategies in
hormone-responsive early breast cancer: the role of aromatase
inhibitors. Onkologie. 2007 Feb;30(1-2):55-64. Epub 2007 Jan 26. Review.
PubMed PMID: 17264527.
124: Ellis MJ, Rigden CE. Initial versus sequential adjuvant aromatase
inhibitor
therapy: a review of the current data. Curr Med Res Opin. 2006
Dec;22(12):2479-87. Review. PubMed PMID: 17257462.
125: Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors
for treatment of advanced breast cancer in postmenopausal women.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in:
Cochrane Database Syst Rev. 2009;(4):CD003370. PubMed PMID: 17253488.
126: Oliveira VM, Aldrighi JM, Rinaldi JF. [Current status of breast
cancer chemoprevention]. Rev Assoc Med Bras. 2006 Nov-Dec;52(6):453-9.
Review. Portuguese. PubMed PMID: 17242785.
127: Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant
treatment of postmenopausal women with early breast cancer: Putting
safety issues into perspective. Breast J. 2007 Jan-Feb;13(1):28-35.
Review. PubMed PMID: 17214790.
128: Barker S. Non-steroidal anti-estrogens in the treatment of breast
cancer. Curr Opin Investig Drugs. 2006 Dec;7(12):1085-91. Review. PubMed
PMID: 17209526.
129: Skedgel C, Rayson D, Dewar R, Younis T. Cost-utility of adjuvant
hormone therapies with aromatase inhibitors in post-menopausal women
with breast cancer:
upfront anastrozole, sequential tamoxifen-exemestane and extended
tamoxifen-letrozole. Breast. 2007 Jun;16(3):252-61. Epub 2007 Jan 4.
PubMed PMID: 17207623.
130: Kaya U, Oktem M, Zeyneloglu HB, Ozen O, Kuscu E. Impact of
aromatase inhibitors on adhesion formation in a rat model. Fertil Steril.
2007 Apr;87(4):934-9. Epub 2006 Dec 14. PubMed PMID: 17173902.
131: Jordan VC, Brodie AM. Development and evolution of therapies
targeted to the estrogen receptor for the treatment and prevention of
breast cancer. Steroids. 2007 Jan;72(1):7-25. Epub 2006 Dec 13. Review.
PubMed PMID: 17169390; PubMed Central PMCID: PMC2566956.
132: Chu QD, McDonald JC, Li BD. Adjuvant therapy for patients who have
node-positive breast cancer. Adv Surg. 2006;40:77-98. Review. PubMed
PMID: 17163096.
133: Andreetta C, Smith I. Adjuvant endocrine therapy for early breast
cancer. Cancer Lett. 2007 Jun 18;251(1):17-27. Epub 2006 Dec 5. Review.
PubMed PMID: 17150303.
134: Dixon JM. Aromatase inhibitors in early breast cancer therapy: a
variety of
treatment strategies. Expert Opin Pharmacother. 2006 Dec;7(18):2465-79.
Review. PubMed PMID: 17150002.
135: Wheler J, Johnson M, Seidman A. Adjuvant therapy with aromatase
inhibitors for postmenopausal women with early breast cancer: evidence
and ongoing controversy. Semin Oncol. 2006 Dec;33(6):672-80. Review.
PubMed PMID: 17145347.
136: Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I,
Greenwood M,
Jakesz R. Effectiveness of switching from adjuvant tamoxifen to
anastrozole in postmenopausal women with hormone-sensitive early-stage
breast cancer: a meta-analysis. Lancet Oncol. 2006 Dec;7(12):991-6.
Erratum in: Lancet Oncol. 2007 Jan;8(1):6. PubMed PMID: 17138220.
137: Monnier A. Effects of adjuvant aromatase inhibitor therapy on lipid
profiles. Expert Rev Anticancer Ther. 2006 Nov;6(11):1653-62. Review.
PubMed PMID: 17134368.
138: Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer
Network Breast Cancer Clinical Practice Guidelines in Oncology; American
Society of Clinical Oncology Technology Assessment on the Use of
Aromatase Inhibitors; St Gallen International Expert Consensus on the
Primary Therapy of Early Breast Cancer. Adjuvant endocrine therapy in
hormone receptor-positive postmenopausal breast cancer: evolution of
NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 2006
Nov;4(10):971-9. Review. PubMed PMID: 17112447.
139: Perez EA. Appraising adjuvant aromatase inhibitor therapy.
Oncologist. 2006
Nov-Dec;11(10):1058-69. Review. PubMed PMID: 17110624.
140: Younis T, Rayson D, Dewar R, Skedgel C. Modeling for
cost-effective-adjuvant aromatase inhibitor strategies for
postmenopausal women with breast cancer. Ann Oncol. 2007
Feb;18(2):293-8. Epub 2006 Nov 9. PubMed PMID: 17095569.
141: Monnier A. Refining the postmenopausal breast cancer treatment
paradigm: the FACE trial. Expert Rev Anticancer Ther. 2006
Oct;6(10):1355-9. Review. PubMed PMID: 17069521.
142: Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know
about the mechanisms of aromatase inhibitor resistance? J Steroid
Biochem Mol Biol. 2006 Dec;102(1-5):232-40. Epub 2006 Oct 19. Review.
PubMed PMID: 17055257; PubMed Central PMCID: PMC1829446.
143: Brueggemeier RW. Update on the use of aromatase inhibitors in
breast cancer. Expert Opin Pharmacother. 2006 Oct;7(14):1919-30. Review.
PubMed PMID: 17020418.
144: Vergote I, Amant F, Leunen K, Van Gorp T, Berteloot P, Neven P.
Metastatic breast cancer: sequencing hormonal therapy and positioning of
fulvestrant. Int J
Gynecol Cancer. 2006;16 Suppl 2:524-6. Review. PubMed PMID: 17010064.
145: Venturini M, Del Mastro L. Safety of adjuvant aromatase inhibitor
therapy. Cancer Treat Rev. 2006 Nov;32(7):548-56. Epub 2006 Sep 27.
Review. PubMed PMID: 17008013.
146: Bertelli G, Paridaens R. Optimal sequence of hormonotherapy in
advanced breast cancer. Curr Opin Oncol. 2006 Nov;18(6):572-7. Review.
PubMed PMID: 16988577.
147: Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with
aromatase inhibitors and inactivators versus standard hormonal therapy
in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006 Sep
20;98(18):1285-91. PubMed PMID: 16985247.
148: Howell A. Pure oestrogen antagonists for the treatment of advanced
breast cancer. Endocr Relat Cancer. 2006 Sep;13(3):689-706. Review.
PubMed PMID: 16954425.
149: Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S,
Conte M,
Fini M, Giavaresi G, Berti P, Miccoli P. Metastatic breast cancer: an
updating. Biomed Pharmacother. 2006 Nov;60(9):548-56. Epub 2006 Aug 28.
Review. PubMed PMID: 16950593.
150: Nabholtz JM, Gligorov J. Cardiovascular safety profiles of
aromatase inhibitors : a comparative review. Drug Saf.
2006;29(9):785-801. Review. Erratum
in: Drug Saf. 2007;30(3):201. PubMed PMID: 16944964.
151: Dodwell D, Pippen J. Time to response: comparison of fulvestrant
and oral endocrine agents. Clin Breast Cancer. 2006 Aug;7(3):244-7.
PubMed PMID: 16942641.
152: Ohsako T, Inoue K, Nagamoto N, Yoshida Y, Nakahara O, Sakamoto N.
Joint symptoms: a practical problem of anastrozole. Breast Cancer.
2006;13(3):284-8. PubMed PMID: 16929123.
153: Spicer J, Ellis P. Towards optimal endocrine therapy for
hormone-sensitive breast cancer: initial versus sequential adjuvant
aromatase inhibition. Cancer Lett. 2007 Apr 18;248(2):165-74. Epub 2006
Aug 21. Review. PubMed PMID: 16919870.
154: Buzdar AU. Aromatase inhibitors: changing the face of endocrine
therapy for
breast cancer. Breast Dis. 2005-2006;24:107-17. Review. PubMed PMID:
16917143.
155: Skedgel C, Rayson D, Dewar R, Younis T. Cost-utility of adjuvant
hormone therapies for breast cancer in post-menopausal women: sequential
tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat.
2007 Mar;101(3):325-33. Epub 2006 Aug 2. PubMed PMID: 16897433.
156: Mouridsen HT. Incidence and management of side effects associated
with aromatase inhibitors in the adjuvant treatment of breast cancer in
postmenopausal women. Curr Med Res Opin. 2006 Aug;22(8):1609-21. Review.
PubMed PMID: 16870085.
157: Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W,
Ravdin P. Defining the role of aromatase inhibitors in the adjuvant
endocrine treatment of
early breast cancer. Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.
PubMed PMID: 16870082.
158: Jakesz R. The adjuvant endocrine treatment revolution: focus on
anastrozole. Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):301-12.
Review. PubMed PMID: 16866615.
159: Fentiman IS. Optimising adjuvant endocrine treatment of breast
cancer with aromatase inhibitors. Int J Clin Pract. 2006
Jun;60(6):689-93. Review. PubMed PMID: 16805754.
160: Buzdar AU, Guastalla JP, Nabholtz JM, Cuzick J, ATAC Trialists'
Group. Impact of chemotherapy regimens prior to endocrine therapy:
Results from the ATAC (Anastrozole and Tamoxifen, Alone or in
Combination) trial. Cancer. 2006 Aug 1;107(3):472-80. Erratum in:
Cancer. 2006;107(9 No 1):2314. PubMed PMID: 16804925.
161: Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP,
Mallett D, Perez EA. Risk of cancer treatment-associated bone loss and
fractures among women with breast cancer receiving aromatase inhibitors.
Clin Breast Cancer. 2006 Jun;7(2):127-32. PubMed PMID: 16800971.
162: Tsukagoshi S. [Introduction of new drug: letrozole, a new
non-steroidal aromatase inhibitor for the treatment of postmenopausal
women with breast cancer]. Gan To Kagaku Ryoho. 2006 Jun;33(6):859-63.
Review. Japanese. PubMed PMID: 16770112.
163: Dunkel L. Use of aromatase inhibitors to increase final height. Mol
Cell Endocrinol. 2006 Jul 25;254-255:207-16. Review. PubMed PMID:
16766117.
164: Gil JM, Rubio-Terrés C, Del Castillo A, González P, Canorea F.
Pharmacoeconomic analysis of adjuvant therapy with exemestane,
anastrozole, letrozole or tamoxifen in postmenopausal women with
operable and estrogen receptor-positive breast cancer. Clin Transl Oncol.
2006 May;8(5):339-48. PubMed
PMID: 16760009.
165: Freedman OC, Verma S, Clemons MJ. Pre-menopausal breast cancer and
aromatase inhibitors: Treating a new generation of women. Breast Cancer
Res Treat. 2006 Oct;99(3):241-7. Epub 2006 Jun 3. Review. PubMed PMID:
16752075.
166: Dunn C, Keam SJ. Letrozole: a pharmacoeconomic review of its use in
postmenopausal women with breast cancer. Pharmacoeconomics.
2006;24(5):495-517. Review. PubMed PMID: 16706574.
167: Grana G. Adjuvant aromatase inhibitor therapy for early breast
cancer: A review of the most recent data. J Surg Oncol. 2006 Jun
1;93(7):585-92. Review. PubMed PMID: 16705732.
168: Juretić A, Sarić N, Bisof V, Basić-Koretić M. [Fulvestrant: a new
agent in endocrine treatment for breast cancer]. Lijec Vjesn. 2006
Jan-Feb;128(1-2):31-6.
Review. Croatian. PubMed PMID: 16640225.
169: Aumiller J. [Advances in the treatment of breast carcinoma. New
therapy schedules with astonishing success quotas]. MMW Fortschr Med.
2006 Mar 23;148(12):4-6, 8. German. PubMed PMID: 16625995.
170: Cheung KL, Owers R, Robertson JF. Endocrine response after prior
treatment with fulvestrant in postmenopausal women with advanced breast
cancer: experience
from a single centre. Endocr Relat Cancer. 2006 Mar;13(1):251-5. PubMed
PMID: 16601292.
171: Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as
initial adjuvant therapy in early breast cancer: Canadian perspectives
on the ATAC completed-treatment analysis. Support Care Cancer. 2006
Sep;14(9):917-27. Epub 2006 Apr 5. PubMed PMID: 16596419.
172: Jinno H, Ikeda T, Takayama S, Kitajima M. [The evolving role of
endocrine therapy for breast cancer]. Nippon Rinsho. 2006
Mar;64(3):547-54. Review. Japanese. PubMed PMID: 16529048.
173: Gltick S. Changing the gold standard in adjuvant therapy for breast
cancer:from tamoxifen to aromatase inhibition. Biomed Pharmacother. 2005
Oct;59 Suppl 2:S321-2. PubMed PMID: 16521302.
174: Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast
cancer: options for therapy after tamoxifen and aromatase inhibitors.
Breast. 2006 Oct;15(5):584-94. Epub 2006 Feb 28. Review. PubMed PMID:
16504510.
175: Aapro M. Improving bone health in patients with early breast cancer
by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Breast. 2006 Feb;15 Suppl 1:S30-40. Review. PubMed PMID: 16500238.
176: Bhatnagar AS. Review of the development of letrozole and its use in
advanced breast cancer and in the neoadjuvant setting. Breast. 2006
Feb;15 Suppl 1:S3-13.
Review. PubMed PMID: 16500235.
177: Miller WR. Aromatase inhibitors and breast cancer. Minerva
Endocrinol. 2006
Mar;31(1):27-46. Review. PubMed PMID: 16498362.
178: Howell A. Fulvestrant ('Faslodex'): current and future role in
breast cancer management. Crit Rev Oncol Hematol. 2006 Mar;57(3):265-73.
Epub 2006 Feb 9. Review. PubMed PMID: 16473018.
179: Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment
for postmenopausal patients with breast cancer: emerging data. Clin
Cancer Res. 2006
Feb 1;12(3 Pt 2):1037s-1048s. PubMed PMID: 16467122.
180: Ingle JN. Adjuvant endocrine therapy for postmenopausal women with
early breast cancer. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1031s-1036s.
PubMed PMID: 16467121.
181: Tuma RS. Latest studies hint at survival advantage with aromatase
inhibitors in early breast cancer. J Natl Cancer Inst. 2006 Jan
18;98(2):86-7. PubMed PMID:
16418506.
182: Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer.
Expert Rev Anticancer Ther. 2006 Jan;6(1):43-7. Review. PubMed PMID:
16375643.
183: Mouridsen HT, Robert NJ. Benefit with aromatase inhibitors in the
adjuvant setting for postmenopausal women with breast cancer. MedGenMed.
2005 Aug 24;7(3):20. Review. PubMed PMID: 16369246; PubMed Central
PMCID: PMC1681642.
184: Berry J. Are all aromatase inhibitors the same? A review of
controlled clinical trials in breast cancer. Clin Ther. 2005
Nov;27(11):1671-84. Review. PubMed PMID: 16368441.
185: Reiter EO, Norjavaara E. Testotoxicosis: current viewpoint. Pediatr
Endocrinol Rev. 2005 Dec;3(2):77-86. Review. PubMed PMID: 16361981.
186: Ferrero S, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Future
perspectives in the medical treatment of endometriosis. Obstet Gynecol
Surv. 2005 Dec;60(12):817-26. Review. PubMed PMID: 16359564.
187: Howell A, Locker GY. Defining the roles of aromatase inhibitors in
the adjuvant treatment of early-stage breast cancer. Clin Breast Cancer.
2005 Oct;6(4):302-9. Review. PubMed PMID: 16277879.
188: Jonat W, Hilpert F, Maass N. The use of aromatase inhibitors in
adjuvant therapy for early breast cancer. Cancer Chemother Pharmacol.
2005 Nov;56 Suppl 1:32-8. Review. PubMed PMID: 16273366.
189: Vergote I, Abram P. Fulvestrant, a new treatment option for
advanced breast
cancer: tolerability versus existing agents. Ann Oncol. 2006
Feb;17(2):200-4. Epub 2005 Oct 26. Review. PubMed PMID: 16251200.
190: Johnston SR, Martin LA, Dowsett M. Life following aromatase
inhibitors--where now for endocrine sequencing? Breast Cancer Res Treat.
2005;93
Suppl 1:S19-25. Review. PubMed PMID: 16247596.
191: Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M.
Retrospective analysis of time to recurrence in the ATAC trial according
to hormone receptor status: an hypothesis-generating study. J Clin Oncol.
2005 Oct 20;23(30):7512-7.
PubMed PMID: 16234518.
192: Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects
of endocrine therapy for breast cancer: implications for cardiovascular
disease prevention in postmenopausal women. Breast. 2006
Jun;15(3):301-12. Epub 2005 Oct
17. Review. PubMed PMID: 16230014.
193: Abrial C, Mouret-Reynier MA, Curé H, Feillel V, Leheurteur M,
Lemery S, Le Bouëdec G, Durando X, Dauplat J, Chollet P. Neoadjuvant
endocrine therapy in breast cancer. Breast. 2006 Feb;15(1):9-19. Epub
2005 Oct 17. Review. PubMed PMID: 16230013.
194: Howell A. New developments in the treatment of postmenopausal
breast cancer. Trends Endocrinol Metab. 2005 Nov;16(9):420-8. Epub 2005
Oct 6. Review. PubMed PMID: 16213745.
195: Dowsett M, Folkerd E, Doody D, Haynes B. The biology of steroid
hormones and endocrine treatment of breast cancer. Breast. 2005
Dec;14(6):452-7. Epub 2005 Sep 28. Review. PubMed PMID: 16198110.
196: Howell A. The future of fulvestrant ("Faslodex"). Cancer Treat Rev.
2005;31
Suppl 2:S26-33. Epub 2005 Sep 28. Review. PubMed PMID: 16198056.
197: Köberle D, Thürlimann B. Adjuvant endocrine therapy in
postmenopausal breast cancer patients. Breast. 2005 Dec;14(6):446-51.
Epub 2005 Sep 16. Review. PubMed
PMID: 16169728.
198: Chowdhury S, Ellis PA. Recent advances in the use of aromatase
inhibitors for women with postmenopausal breast cancer. J Br Menopause
Soc. 2005 Sep;11(3):96-102. Review. PubMed PMID: 16157000.
199: Henderson IC, Piccart-Gebhart MJ. The evolving role of aromatase
inhibitors
in adjuvant breast cancer therapy. Clin Breast Cancer. 2005
Aug;6(3):206-15. Review. PubMed PMID: 16137430.
200: Stebbing J. Breast cancer--22nd annual symposium. 8-11 December
1999, San Antonio, TX, USA. IDrugs. 2000 Mar;3(3):289-91. PubMed PMID:
16103936.
201: Bertelli G. Sequencing of aromatase inhibitors. Br J Cancer. 2005
Aug;93 Suppl 1:S6-9. Review. PubMed PMID: 16100523; PubMed Central
PMCID: PMC2361690.
202: Bundred NJ. The effects of aromatase inhibitors on lipids and
thrombosis. Br J Cancer. 2005 Aug;93 Suppl 1:S23-7. Review. PubMed PMID:
16100522; PubMed Central PMCID: PMC2361692.
203: Mouridsen HT, Robert NJ. The role of aromatase inhibitors as
adjuvant therapy for early breast cancer in postmenopausal women. Eur J
Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review. PubMed PMID:
16098456.
204: Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P,
Fabi A, Nisticň C, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M,
Terzoli E, Cognetti F. New aromatase inhibitors as second-line endocrine
therapy in postmenopausal patients with metastatic breast carcinoma: a
pooled analysis of the randomized trials. Cancer. 2005 Oct
1;104(7):1335-42. Review. PubMed PMID: 16088965.
205: Gradishar WJ. Safety considerations of adjuvant therapy in early
breast cancer in postmenopausal women. Oncology. 2005;69(1):1-9. Epub
2005 Jul 28. Review. PubMed PMID: 16088229.
206: Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C,
Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G,
Kaufmann M, Wolfgang J; ABCSG and the GABG. Switching of postmenopausal
women with endocrine-responsive early breast cancer to anastrozole after
2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO
95 trial. Lancet. 2005 Aug 6-12;366(9484):455-62. PubMed PMID: 16084253.
207: Baum M. Adjuvant endocrine therapy in postmenopausal women with
early breast cancer: where are we now? Eur J Cancer. 2005
Aug;41(12):1667-77. Review. PubMed PMID: 16046117.
208: Cuzick J. Anastrozole. Drugs Today (Barc). 2005 Apr;41(4):227-39.
Review. PubMed PMID: 16034487.
209: Dixon JM, Renshaw L, Murray J, Macaskill EJ, Young O, Miller WR.
Surgical issues surrounding use of aromatase inhibitors. J Steroid
Biochem Mol Biol. 2005
May;95(1-5):97-103. PubMed PMID: 16023854.
210: Gradishar W. Fulvestrant in the treatment of postmenopausal women
with advanced breast cancer. Expert Rev Anticancer Ther. 2005
Jun;5(3):445-53. Review. PubMed PMID: 16001952.
211: Adjuvant hormone therapy for breast cancer: alternatives to
tamoxifen. Prescrire Int. 2005 Jun;14(77):108-10. PubMed PMID: 15984106.
212: Ponzone R, Sismondi P. Selected highlights from the 27th San
Antonio Breast
Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004. Expert Opin
Pharmacother. 2005 Jun;6(7):1257-67. PubMed PMID: 15957978.
213: Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced
breast cancer. J Steroid Biochem Mol Biol. 2005 May;95(1-5):113-9.
PubMed PMID: 15939585.
214: Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE,
Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for
the treatment of advanced breast carcinoma: a prospectively planned
combined survival analysis of
two multicenter trials. Cancer. 2005 Jul 15;104(2):236-9. PubMed PMID:
15937908.
215: Howell A, Cuzick J. Vascular effects of aromatase inhibitors: data
from clinical trials. J Steroid Biochem Mol Biol. 2005
May;95(1-5):143-9. Erratum in:
J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):180. PubMed PMID: 15936188.
216: Dodwell D, Vergote I. A comparison of fulvestrant and the
third-generation aromatase inhibitors in the second-line treatment of
postmenopausal women with advanced breast cancer. Cancer Treat Rev. 2005
Jun;31(4):274-82. Review. PubMed PMID: 15908126.
217: Spano JP, Khayat D, Delozier T. [Aromatase inhibitors in adjuvant
setting in breast cancer]. Bull Cancer. 2004 Dec 1;91 Suppl 4:S239-43.
Review. French. PubMed PMID: 15899615.
218: Kalidas M, Brown P. Aromatase inhibitors for the treatment and
prevention of breast cancer. Clin Breast Cancer. 2005 Apr;6(1):27-37.
Review. PubMed PMID: 15899070.
219: Anastrozole: new indication. Adjuvant treatment of non metastatic
breast cancer: useful for some patients. Prescrire Int. 2005
Apr;14(76):43-4. PubMed PMID: 15875334.
220: Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant
in postmenopausal women with hormone receptor-positive breast cancer.
Clin Breast Cancer. 2005 Apr;6 Suppl 1:S9-14. Review. PubMed PMID:
15865850.
221: Gradishar WJ, Sahmoud T. Current and future perspectives on
fulvestrant. Clin Breast Cancer. 2005 Apr;6 Suppl 1:S23-9. PubMed PMID:
15865847.
222: Come SE, Borges VF. Role of fulvestrant in sequential hormonal
therapy for advanced, hormone receptor-positive breast cancer in
postmenopausal women. Clin Breast Cancer. 2005 Apr;6 Suppl 1:S15-22.
Review. PubMed PMID: 15865846.
223: Howell A, Buzdar A. Are aromatase inhibitors superior to
antiestrogens? J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):237-47.
Review. PubMed PMID: 15860266.
224: Joensuu H, Ejlertsen B, Lřnning PE, Rutqvist LE. Aromatase
inhibitors in the treatment of early and advanced breast cancer. Acta
Oncol. 2005;44(1):23-31. Review. PubMed PMID: 15848903.
225: Geisler J, Lřnning PE. Aromatase inhibition: translation into a
successful therapeutic approach. Clin Cancer Res. 2005 Apr
15;11(8):2809-21. Review. PubMed
PMID: 15837728.
226: Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in
the treatment of breast cancer. Endocr Rev. 2005 May;26(3):331-45. Epub
2005 Apr 6. Review. PubMed PMID: 15814851.
227: Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex)
in postmenopausal women with hormone receptor-positive advanced breast
cancer. Cancer Invest. 2005;23(2):173-81. Review. PubMed PMID: 15813510.
228: Jakesz R. [New strategies against breast carcinoma. To outwit the
resistance tendency of tumor cells]. MMW Fortschr Med. 2005 Mar
10;147(10):8. German. PubMed PMID: 15803774.
229: Aumiller J. [Breast carcinoma: new, much promising trends. The
cancer anxiety of women -- will be taken better care soon?]. MMW
Fortschr Med. 2005 Mar
10;147(10):4-6. German. PubMed PMID: 15803773.
230: Gralow JR. Optimizing the treatment of metastatic breast cancer.
Breast Cancer Res Treat. 2005;89 Suppl 1:S9-S15. Review. PubMed PMID:
15770536.
231: Longo F, Mansueto G. [AIOM Conference 2004. Endocrine therapy and
management of patients with bone metastasis of breast cancer]. Tumori.
2004 Nov-Dec;90(6):1-12. Italian. PubMed PMID: 15762372.
232: Kaplow R. Innovations in antineoplastic therapy. Nurs Clin North
Am. 2005 Mar;40(1):77-94. Review. PubMed PMID: 15733948.
233: Henderson IC. Aromatase inhibitors in the management of early
breast cancer: optimizing the clinical benefit. Semin Oncol. 2004
Dec;31(6 Suppl 12):31-4. Review. PubMed PMID: 15719599.
234: Smith IE. Aromatase inhibitors in early breast cancer therapy.
Semin Oncol.
2004 Dec;31(6 Suppl 12):9-14. Review. PubMed PMID: 15719596.
235: Mouridsen HT. Aromatase inhibitors in advanced breast cancer. Semin
Oncol. 2004 Dec;31(6 Suppl 12):3-8. Review. PubMed PMID: 15719595.
236: Michaud LB. Adjuvant use of aromatase inhibitors in postmenopausal
women with breast cancer. Am J Health Syst Pharm. 2005 Feb
1;62(3):266-73. Review. PubMed PMID: 15719584.
237: Rao GG, Miller DS. Clinical applications of hormonal therapy in
ovarian cancer. Curr Treat Options Oncol. 2005 Mar;6(2):97-102. Review.
PubMed PMID: 15717991.
238: Freedman OC, Verma S, Clemons MJ. Using aromatase inhibitors in the
neoadjuvant setting: evolution or revolution? Cancer Treat Rev. 2005
Feb;31(1):1-17. Epub 2004 Nov 18. Review. PubMed PMID: 15707700.
239: Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C,
Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh
G; IMPACT Trialists. Short-term changes in Ki-67 during neoadjuvant
treatment of primary breast cancer with anastrozole or tamoxifen alone
or combined correlate with recurrence-free survival. Clin Cancer Res.
2005 Jan 15;11(2 Pt 2):951s-8s. PubMed PMID: 15701892.
240: Ingle JN. Endocrine therapy trials of aromatase inhibitors for
breast cancer in the adjuvant and prevention settings. Clin Cancer Res.
2005 Jan 15;11(2 Pt 2):900s-5s. Review. PubMed PMID: 15701884.
241: Beck JI, Boothroyd C, Proctor M, Farquhar C, Hughes E. Oral anti-oestrogens
and medical adjuncts for subfertility associated with anovulation.
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002249. Review. Update in:
Cochrane Database Syst Rev. 2009;(4):CD002249. PubMed PMID: 15674894.
242: Travis K. Anastrozole data show continued delay in relapse, but no
clear survival advantage. J Natl Cancer Inst. 2005 Jan 19;97(2):86-7.
PubMed PMID: 15657334.
243: Fentiman IS. Aromatase inhibitors and breast cancer: time for a
change? Int
J Clin Pract. 2004 Dec;58(12):1152-8. Review. PubMed PMID: 15646413.
244: Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF,
Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial
after completion of 5 years' adjuvant treatment for breast cancer.
Lancet. 2005 Jan 1-7;365(9453):60-2. PubMed PMID: 15639680.
245: Harwood KV. Advances in endocrine therapy for breast cancer:
considering efficacy, safety, and quality of life. Clin J Oncol Nurs.
2004 Dec;8(6):629-37. Review. PubMed PMID: 15637958.
246: Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related
cancers: breast cancer. J Clin Oncol. 2005 Jan 10;23(2):357-67. Review.
PubMed PMID: 15637398.
247: de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B,
Fourquet A, Pierga JY. [Tamoxifen and aromatase inhibitors in the
treatment of breast cancer in menopausal women: pharmacological and
clinical aspects]. Bull Cancer. 2004 Dec;91(12):917-27. Review. French.
PubMed PMID: 15634633.
248: Buzdar A, Macahilig C. How rapidly do oncologists respond to
clinical trial
data? Oncologist. 2005 Jan;10(1):15-21. PubMed PMID: 15632249.
249: Nabholtz JM. Changes in endocrine therapy: anastrozole and advanced
breast cancer in postmenopausal women. Am J Hosp Palliat Care. 2004
Nov-Dec;21(6):457-65. Review. PubMed PMID: 15612238.
250: Dixon JM. The scientific value of preoperative studies and how they
can be used. Breast Cancer Res Treat. 2004;87 Suppl 1:S19-26. Review.
PubMed PMID: 15597217.
251: Dowsett M. Biomarker investigations from the ATAC trial: the role
of TA01. Breast Cancer Res Treat. 2004;87 Suppl 1:S11-8. PubMed PMID:
15597216.
252: Lynn J. Fulvestrant ('Faslodex')--a new hormonal treatment for
advanced breast cancer. Eur J Oncol Nurs. 2004;8 Suppl 2:S83-8. Review.
PubMed PMID: 15590319.
253: Aapro MS. Long-term implications of bone loss in breast cancer.
Breast. 2004 Dec;13 Suppl 1:S29-37. Review. PubMed PMID: 15585380.
254: Jänicke F. Are all aromatase inhibitors the same? A review of the
current evidence. Breast. 2004 Dec;13 Suppl 1:S10-8. Review. PubMed
PMID: 15585378.
255: Huober J, Krainick-Strobel U, Kurek R, Wallwiener D. Neoadjuvant
endocrine therapy in primary breast cancer. Clin Breast Cancer. 2004
Dec;5(5):341-7. Review. PubMed PMID: 15585070.
256: Possinger K. Fulvestrant - a new treatment for postmenopausal women
with hormone-sensitive advanced breast cancer. Expert Opin Pharmacother.
2004 Dec;5(12):2549-58. PubMed PMID: 15571471.
257: Tobias JS. Recent advances in endocrine therapy for postmenopausal
women with early breast cancer: implications for treatment and
prevention. Ann Oncol. 2004 Dec;15(12):1738-47. Review. PubMed PMID:
15550578.
258: Robertson JF. Selective oestrogen receptor modulators/new
antioestrogens: a
clinical perspective. Cancer Treat Rev. 2004 Dec;30(8):695-706. Review.
PubMed PMID: 15541579.
259: Buzdar AU. Fulvestrant: a new type of estrogen receptor antagonist
for the treatment of advanced breast cancer. Drugs Today (Barc). 2004
Sep;40(9):751-64. Review. PubMed PMID: 15538548.
260: Howell A, Dowsett M. Endocrinology and hormone therapy in breast
cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res.
2004;6(6):269-74.
Epub 2004 Oct 6. Review. PubMed PMID: 15535858; PubMed Central PMCID:
PMC1064088.
261: Gadducci A, Cosio S, Genazzani AR. Use of estrogen antagonists and
aromatase inhibitors in breast cancer and hormonally sensitive tumors of
the uterine body.
Curr Opin Investig Drugs. 2004 Oct;5(10):1031-44. Review. PubMed PMID:
15535424.
262: Marchetti M, Caruggi M, Colombo G. Cost utility and budget impact
of third-generation aromatase inhibitors for advanced breast cancer: a
literature-based model analysis of costs in the Italian National Health
Service.
Clin Ther. 2004 Sep;26(9):1546-61. PubMed PMID: 15531017.
263: Morales L, Neven P, Timmerman D, Christiaens MR, Vergote I, Van
Limbergen E, Carbonez A, Van Huffel S, Ameye L, Paridaens R. Acute
effects of tamoxifen and third-generation aromatase inhibitors on
menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004
Sep;15(8):753-60. PubMed PMID: 15494636.
264: Grana G. Shifting paradigms in hormonal therapy for breast cancer.
Cancer Biol Ther. 2004 Sep;3(9):797-805. Epub 2004 Sep 2. Review. PubMed
PMID: 15467423.
265: Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL,
Hortobagyi G. The role of aromatase inhibitors in the adjuvant treatment
of breast carcinoma: the M. D. Anderson Cancer Center evidence-based
approach. Cancer. 2004 Oct 1;101(7):1482-9. Review. PubMed PMID:
15378476.
266: Fricker J. Beating breast cancer. Nurs Stand. 2004 Aug
11-17;18(48):15. PubMed PMID: 15366393.
267: Chung CT, Carlson RW. Adjuvant aromatase inhibitors following
tamoxifen for
early-stage breast cancer in postmenopausal women: what do we really
know? Clin Breast Cancer. 2004 Sep;5 Suppl 1:S18-23. Review. PubMed
PMID: 15347435.
268: Boccardo F. Switching trial of adjuvant tamoxifen with an aromatase
inhibitor in postmenopausal patients with breast cancer. Clin Breast
Cancer. 2004 Sep;5 Suppl 1:S13-7. Review. PubMed PMID: 15347434.
269: Buzdar AU. The ATAC (Arimidex, Tamoxifen, Alone or in Combination)
trial: an update. Clin Breast Cancer. 2004 Sep;5 Suppl 1:S6-S12. Review.
PubMed PMID: 15347433.
270: Tobias JS, Howell A. An open randomised trial of second-line
endocrine therapy in advanced breast cancer: comparison of the Aromatase
inhibitors letrozole and anastrozole. Eur J Cancer. 2004
Aug;40(12):1913. PubMed PMID: 15288295.
271: Baum M. Current status of aromatase inhibitors in the management of
breast cancer and critique of the NCIC MA-17 trial. Cancer Control. 2004
Jul-Aug;11(4):217-21. Review. PubMed PMID: 15284712.
272: Riepe FG, Baus I, Wiest S, Krone N, Sippell WG, Partsch CJ.
Treatment of pubertal gynecomastia with the specific aromatase inhibitor
anastrozole. Horm Res. 2004;62(3):113-8. Epub 2004 Jul 20. PubMed PMID:
15273427.
273: Koshizuka K, Serizawa M, Hasuda N, Furuya K, Mouri N, Takano K,
Matsumoto M. [Tamoxifen-induced severe hypertriglyceridemia--report of 3
cases]. Gan To Kagaku Ryoho. 2004 Jul;31(7):1109-12. Japanese. PubMed
PMID: 15272596.
274: Baumann ChK, Aebi S. [Aromatase inhibitors in the adjuvant therapy
of breast carcinomas]. Ther Umsch. 2004 Jun;61(6):359-64. Review.
German. PubMed PMID: 15253160.
275: Azria D, Lemanski C, Zouhair A, Gutowski M, Belkacémi Y, Dubois JB,
Romieu G, Ozsahin M. [Adjuvant treatment of breast cancer by concomitant
hormonotherapy
and radiotherapy: state of the art]. Cancer Radiother. 2004
Jun;8(3):188-96. Review. French. PubMed PMID: 15217586.
276: Gamucci T. [The ATAC study on adjuvants in breast cancer. What kind
of repercussions will it have on clinical practice?]. Suppl Tumori. 2004
Jul-Aug;3(4):S16. Italian. PubMed PMID: 15206201.
277: Bravi S. [The ATAC study on adjuvants in breast cancer]. Suppl
Tumori. 2004
Jul-Aug;3(4):S15. Italian. PubMed PMID: 15206200.
278: Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker
LM, Gertler S, Harrison MP, Clarke DA. Pharmacokinetic profile of
intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet.
2004;43(8):529-38. PubMed PMID: 15170367.
279: Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in
postmenopausal women with breast cancer. Drugs. 2004;64(11):1213-30.
Review. PubMed PMID: 15161328.
280: Sainsbury R. Aromatase inhibition in the treatment of advanced
breast cancer: is there a relationship between potency and clinical
efficacy? Br J Cancer. 2004 May 4;90(9):1733-9. Review. PubMed PMID:
15150604; PubMed Central PMCID: PMC2410276.
281: Clemons M, Coleman RE, Verma S. Aromatase inhibitors in the
adjuvant setting: bringing the gold to a standard? Cancer Treat Rev.
2004 Jun;30(4):325-32. Review. PubMed PMID: 15145507.
282: Wong ZW, Ellis MJ. Neoadjuvant endocrine therapy for breast cancer:
an overlooked option? Oncology (Williston Park). 2004 Apr;18(4):411-20;
discussion 421, 424, 429 passim. Review. PubMed PMID: 15134351.
283: Buzdar AU, Vergote I, Sainsbury R. The impact of hormone receptor
status on
the clinical efficacy of the new-generation aromatase inhibitors: a
review of data from first-line metastatic disease trials in
postmenopausal women. Breast J. 2004 May-Jun;10(3):211-7. PubMed PMID:
15125747.
284: Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O,
Perey L, Aebi S, Rochlitz C, Goldhirsch A. Anastrozole ('Arimidex')
versus tamoxifen as first-line therapy in postmenopausal women with
advanced breast cancer: results of the double-blind cross-over SAKK
trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex'
Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res
Treat. 2004 Jun;85(3):247-54. PubMed PMID: 15111763.
285: Guarneri V, Conte PF. The curability of breast cancer and the
treatment of advanced disease. Eur J Nucl Med Mol Imaging. 2004 Jun;31
Suppl 1:S149-61. Epub 2004 Apr 24. Review. PubMed PMID: 15107948.
286: Johnston S. Fulvestrant and the sequential endocrine cascade for
advanced breast cancer. Br J Cancer. 2004 Mar;90 Suppl 1:S15-8. Review.
PubMed PMID: 15094760; PubMed Central PMCID: PMC2750772.
287: Vergote I, Robertson JF. Fulvestrant is an effective and
well-tolerated endocrine therapy for postmenopausal women with advanced
breast cancer: results from clinical trials. Br J Cancer. 2004 Mar;90
Suppl 1:S11-4. Review. PubMed PMID: 15094759; PubMed Central PMCID:
PMC2750769.
288: Brueggemeier RW. Aromatase inhibitors: new endocrine treatment of
breast cancer. Semin Reprod Med. 2004 Feb;22(1):31-43. Review. PubMed
PMID: 15083379.
289: Kahlert S, von Koch F, Ditsch N, Untch M. [Adjuvant treatment of
breast cancer in 2004. A review of the 8th consensus conference of St.
Gallen and new study results]. Gynakol Geburtshilfliche Rundsch. 2004
Apr;44(2):102-12. Review.
German. PubMed PMID: 15073439.
290: Arora A, Potter JF. Aromatase inhibitors: current indications and
future prospects for treatment of postmenopausal breast cancer. J Am
Geriatr Soc. 2004 Apr;52(4):611-6. Review. PubMed PMID: 15066080.
291: Campos SM. Aromatase inhibitors for breast cancer in postmenopausal
women. Oncologist. 2004;9(2):126-36. Review. PubMed PMID: 15047917.
292: Major MA. Clinical trials update: Medical management of advanced
breast cancer. Cancer Nurs. 2003 Dec;26(6 Suppl):10S-15S. Review. PubMed
PMID: 15025407.
293: Grana G. New developments in endocrine therapy: role of adjuvant
therapy for early breast cancer. Cancer Nurs. 2003 Dec;26(6 Suppl):4S-9S.
Review. PubMed PMID: 15025406.
294: McKeage K, Curran MP, Plosker GL. Fulvestrant: a review of its use
in hormone receptor-positive metastatic breast cancer in postmenopausal
women with disease progression following antiestrogen therapy. Drugs.
2004;64(6):633-48. Review. PubMed PMID: 15018596.
295: Serrano D, Perego E, Costa A, Decensi A. Progress in
chemoprevention of breast cancer. Crit Rev Oncol Hematol. 2004
Feb;49(2):109-17. Review. PubMed PMID: 15012972.
296: Kawakami M, Saji S, Toi M. [Controversies in endocrine therapy for
breast cancer]. Gan To Kagaku Ryoho. 2004 Feb;31(2):181-7. Review.
Japanese. PubMed PMID: 14997748.
297: Buzdar AU. Hormonal therapy in early and advanced breast cancer.
Breast J. 2004 Jan-Feb;10 Suppl 1:S19-21. Review. PubMed PMID: 14984485.
298: Domont J, Namer M, Khayat D, Spano JP. [Neoadjuvant endocrine
therapy for breast cancer: an overview]. Bull Cancer. 2004
Jan;91(1):55-62. Review. French. PubMed PMID: 14975805.
299: Kammerer S. [New prevention strategies against breast cancer and
cervical carcinoma. What can you advice to your patients]. MMW Fortschr
Med. 2003 Dec 11;145(50):4-6. German. PubMed PMID: 14963962.
300: Goss PE, Strasser-Weippl K. Prevention strategies with aromatase
inhibitors. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):372S-9S. PubMed PMID:
14734494.
301: Ingle JN. Sequencing of endocrine therapy in postmenopausal women
with advanced breast cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt
2):362S-7S. PubMed PMID: 14734492.
302: Buzdar AU. Data from the Arimidex, tamoxifen, alone or in
combination (ATAC) trial: implications for use of aromatase inhibitors
in 2003. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):355S-61S. PubMed PMID:
14734491.
303: Howell A, Osborne CK, Mauriac L. Spreading the word, but not too
thinly. Lancet. 2004 Jan 10;363(9403):165-6. PubMed PMID: 14726176.
304: Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer:
aromatase inhibitor or antioestrogen? Br J Cancer. 2004 Jan
12;90(1):20-5. Review. PubMed PMID: 14710200; PubMed Central PMCID:
PMC2395329.
305: Howell A, Robertson JF, Vergote I. A review of the efficacy of
anastrozole in postmenopausal women with advanced breast cancer with
visceral metastases. Breast Cancer Res Treat. 2003 Dec;82(3):215-22.
Review. PubMed PMID: 14703069.
306: Simons WR, Jones D, Buzdar A. Cost-effectiveness of anastrozole
versus tamoxifen as first-line therapy for postmenopausal women with
advanced breast cancer. Clin Ther. 2003 Nov;25(11):2972-87. PubMed PMID:
14693319.
307: Goss PE, Strasser-Weippl K. Aromatase inhibitors for
chemoprevention. Best Pract Res Clin Endocrinol Metab. 2004
Mar;18(1):113-30. Review. PubMed PMID: 14687601.
308: Howell SJ, Johnston SR, Howell A. The use of selective estrogen
receptor modulators and selective estrogen receptor down-regulators in
breast cancer. Best Pract Res Clin Endocrinol Metab. 2004
Mar;18(1):47-66. Review. PubMed PMID: 14687597.
309: Mokbel K. Focus on anastrozole and breast cancer. Curr Med Res Opin.
2003;19(8):683-8. Review. PubMed PMID: 14687437.
310: Buzdar AU. Aromatase inhibitors in breast cancer therapy. Clin
Breast Cancer. 2003 Nov;4 Suppl 2:S84-8. Review. PubMed PMID: 14667279.
311: Mouridsen HT, Rose C, Brodie AH, Smith IE. Challenges in the
endocrine management of breast cancer. Breast. 2003 Aug;12 Suppl
2:S2-19. Review. PubMed PMID: 14659138.
312: Smith IE. Hormonal therapy: introduction. Breast. 2003 Aug;12 Suppl
2:S1. PubMed PMID: 14659137.
313: Pritchard KI. The best use of adjuvant endocrine treatments.
Breast. 2003 Dec;12(6):497-508. Review. PubMed PMID: 14659127.
314: Serrano D, Bonanni B, Cazzaniga M, Galli A, Gonzaga AG, Decensi A.
Pharmacological prevention of breast cancer: quo vadis? Breast. 2003
Dec;12(6):379-86. Review. PubMed PMID: 14659109.
315: Davidson NE, Visvanathan K, Emens L. New findings about endocrine
therapy for breast cancer. Breast. 2003 Dec;12(6):368-72. Review. PubMed
PMID: 14659107.
316: Aprikian AG, Fleshner N, Langleben A, Hames J. An oncology
perspective on the benefits and cost of combined androgen blockade in
advanced prostate cancer.
Can J Urol. 2003 Oct;10(5):1986-94. PubMed PMID: 14633326.
317: Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The
pharmacology of letrozole. J Steroid Biochem Mol Biol. 2003
Oct;87(1):35-45. Review. PubMed PMID: 14630089.
318: Goss PE. Breast cancer prevention--clinical trials strategies
involving aromatase inhibitors. J Steroid Biochem Mol Biol. 2003
Sep;86(3-5):487-93. Review. PubMed PMID: 14623548.
319: Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G, Dixon JM. An
integrated view of aromatase and its inhibition. J Steroid Biochem Mol
Biol. 2003 Sep;86(3-5):413-21. Review. PubMed PMID: 14623539.
320: Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of
hormone therapy on cognition in breast cancer. J Steroid Biochem Mol
Biol. 2003 Sep;86(3-5):405-12. Erratum in: J Steroid Biochem Mol Biol.
2005 Jun;96(1):93. PubMed PMID: 14623538.
321: Ingle JN, Suman VJ. Aromatase inhibitors versus tamoxifen for
management of
postmenopausal breast cancer in the advanced disease and neoadjuvant
settings. J
Steroid Biochem Mol Biol. 2003 Sep;86(3-5):313-9. Review. PubMed PMID:
14623527.
322: Coombes RC, Gibson L, Hall E, Emson M, Bliss J. Aromatase
inhibitors as adjuvant therapies in patients with breast cancer. J
Steroid Biochem Mol Biol. 2003 Sep;86(3-5):309-11. Review. PubMed PMID:
14623526.
323: Ellis MJ, Rosen E, Dressman H, Marks J. Neoadjuvant comparisons of
aromatase inhibitors and tamoxifen: pretreatment determinants of
response and on-treatment
effect. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):301-7. Review.
PubMed PMID:
14623525.
324: Dixon JM, Jackson J, Renshaw L, Miller WR. Neoadjuvant tamoxifen
and aromatase inhibitors: comparisons and clinical outcomes. J Steroid
Biochem Mol Biol. 2003 Sep;86(3-5):295-9. Review. PubMed PMID: 14623524.
325: Buzdar AU. Role of anastrozole in adjuvant therapy for
postmenopausal patients. Semin Oncol. 2003 Oct;30(5 Suppl 16):21-9.
Review. PubMed PMID: 14613023.
326: Jones SE. Fulvestrant: an estrogen receptor antagonist that
downregulates the estrogen receptor. Semin Oncol. 2003 Oct;30(5 Suppl
16):14-20. Review. PubMed PMID: 14613022.
327: Baum M, Buzdar A, Howell A. ATAC trial did not report interim
results. BMJ.
2003 Nov 1;327(7422):1050. PubMed PMID: 14593064; PubMed Central PMCID:
PMC261674.
328: Fleming GF. Adjuvant aromatase inhibitors: are we there yet?
Cancer. 2003 Nov 1;98(9):1779-81. PubMed PMID: 14584057.
329: Thürlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J;
Arimidex Study Group. Efficacy of tamoxifen following anastrozole ('Arimidex')
compared with anastrozole following tamoxifen as first-line treatment
for advanced breast
cancer in postmenopausal women. Eur J Cancer. 2003 Nov;39(16):2310-7.
PubMed PMID: 14556922.
330: Bross PF, Baird A, Chen G, Jee JM, Lostritto RT, Morse DE, Rosario
LA, Williams GM, Yang P, Rahman A, Williams G, Pazdur R. Fulvestrant in
postmenopausal women with advanced breast cancer. Clin Cancer Res. 2003
Oct 1;9(12):4309-17. Review. PubMed PMID: 14555500.
331: Hortobagyi GN. Future directions in the endocrine therapy of breast
cancer.
Breast Cancer Res Treat. 2003;80 Suppl 1:S37-9. PubMed PMID: 14535533.
332: Aapro MS, Forbes JF. Three years' follow-up from the ATAC trial is
sufficient to change clinical practice: a debate. Breast Cancer Res
Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. Review. PubMed PMID:
14535530.
333: Mauriac L, Smith I. Aromatase inhibitors in early breast cancer
treatment. Semin Oncol. 2003 Aug;30(4 Suppl 14):46-57. Review. PubMed
PMID: 14513436.
334: Mouridsen H, Gershanovich M. The role of aromatase inhibitors in
the treatment of metastatic breast cancer. Semin Oncol. 2003 Aug;30(4
Suppl 14):33-45. Review. PubMed PMID: 14513435.
335: Should aromatase inhibitors replace tamoxifen? Drug Ther Bull. 2003
Aug;41(8):57-9. Review. PubMed PMID: 12966738.
336: Gradishar WJ, O'Regan RM. Progress in systemic adjuvant therapy of
early-stage breast cancer. Int J Clin Oncol. 2003 Aug;8(4):239-47.
Review. PubMed PMID: 12955580.
337: Carlini P, Ferretti G, Di Cosimo S, Colella E, Tonachella R, Romiti
A, Tomao S, Frassoldati A, Papaldo P, Fabi A, Ruggeri EM, Cognetti F. Is
there a benefit by the sequence anastrozole-formestane for
postmenopausal metastatic breast cancer women? J Steroid Biochem Mol
Biol. 2003 Jul;86(1):107-9. PubMed PMID: 12943750.
338: Jackson J, Miller WR, Dixon JM. Safety issues surrounding the use
of aromatase inhibitors in breast cancer. Expert Opin Drug Saf. 2003
Jan;2(1):73-86. Review. PubMed PMID: 12904126.
339: Cuzick J. Aromatase inhibitors in prevention--data from the ATAC (arimidex,
tamoxifen alone or in combination) trial and the design of IBIS-II (the
second International Breast Cancer Intervention Study). Recent Results
Cancer Res. 2003;163:96-103; discussion 264-6. Review. PubMed PMID:
12903846.
340: Goss PE. Emerging role of aromatase inhibitors in the adjuvant
setting. Am J Clin Oncol. 2003 Aug;26(4):S27-33. Review. PubMed PMID:
12902874.
341: Brodie AH, Mouridsen HT. Applicability of the intratumor aromatase
preclinical model to predict clinical trial results with endocrine
therapy. Am J
Clin Oncol. 2003 Aug;26(4):S17-26. Review. PubMed PMID: 12902873.
342: Rose C. A comparison of the efficacy of aromatase inhibitors in
second-line
treatment of metastatic breast cancer. Am J Clin Oncol. 2003
Aug;26(4):S9-16. Review. PubMed PMID: 12902872.
343: Buzdar AU. Advances in endocrine treatments for postmenopausal
women with metastatic and early breast cancer. Oncologist.
2003;8(4):335-41. Review. PubMed
PMID: 12897330.
344: Verma S, Rocchi A. Economic evaluation of antiaromatase agents in
the second-line treatment of metastatic breast cancer. Support Care
Cancer. 2003 Nov;11(11):728-34. Epub 2003 Jul 22. PubMed PMID: 12883965.
345: Baum M, Buzdar A. The current status of aromatase inhibitors in the
management of breast cancer. Surg Clin North Am. 2003 Aug;83(4):973-94.
Review. PubMed PMID: 12875605.
346: Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M,
Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris
C. Fulvestrant versus anastrozole for the treatment of advanced breast
carcinoma in postmenopausal women: a prospective combined analysis of
two multicenter trials.
Cancer. 2003 Jul 15;98(2):229-38. PubMed PMID: 12872340.
347: Sayer HG, Höffken K. [Hormone therapy, chemotherapy and
immunotherapy in breast carcinoma. The best strategy for your patient].
MMW Fortschr Med. 2003 Jun 12;145(24):40-2. German. PubMed PMID:
12866298.
348: Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac
L; Trial
0020 Investigators; Trial 0021 Investigators. Postmenopausal women who
progress on fulvestrant ('Faslodex') remain sensitive to further
endocrine therapy. Breast Cancer Res Treat. 2003 May;79(2):207-11.
PubMed PMID: 12825855.
349: Goodare H, Dimmer C, Page K. ATAC trial: reporting interim results
is not helpful. BMJ. 2003 Jun 14;326(7402):1329. PubMed PMID: 12805189;
PubMed Central PMCID: PMC1126206.
350: Mortimer JE, Urban JH. Long-term toxicities of selective
estrogen-receptor modulators and antiaromatase agents. Oncology
(Williston Park). 2003 May;17(5):652-9; discussion 659, 662, 666 passim.
Review. PubMed PMID: 12800793.
351: Dranitsaris G, Verma S, Trudeau M. Cost utility analysis of
first-line hormonal therapy in advanced breast cancer: comparison of two
aromatase inhibitors to tamoxifen. Am J Clin Oncol. 2003
Jun;26(3):289-96. PubMed PMID: 12796603.
352: Wu K, Brown P. Is low-dose tamoxifen useful for the treatment and
prevention of breast cancer? J Natl Cancer Inst. 2003 Jun
4;95(11):766-7. Review. PubMed PMID: 12783921.
353: Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK.
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment
of advanced breast cancer in subgroups of postmenopausal women with
visceral and non-visceral metastases: combined results from two
multicentre trials. Eur J Cancer. 2003 Jun;39(9):1228-33. PubMed PMID:
12763210.
354: Campos SM, Winer EP. Hormonal therapy in postmenopausal women with
breast cancer. Oncology. 2003;64(4):289-99. Review. PubMed PMID:
12759523.
355: Buzdar A. Anastrozole as adjuvant therapy for early-stage breast
cancer: implications of the ATAC trial. Clin Breast Cancer. 2003 Apr;4
Suppl 1:S42-8. Review. PubMed PMID: 12756078.
356: Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM,
Gradishar WJ, Grana G, Howell A, Mamounas EP. A roundtable discussion of
aromatase inhibitors as therapy for breast cancer. Breast J. 2003
May-Jun;9(3):213-22. Review. PubMed PMID: 12752630.
357: Kelleher M, Miles D. 21. The adjuvant treatment of breast cancer.
Int J Clin Pract. 2003 Apr;57(3):195-9. Review. PubMed PMID: 12723723.
358: Tamaki Y, Miyoshi Y, Kim SJ, Tanji Y, Taguchi T, Noguchi S.
Aromatase inhibitors for treatment of postmenopausal patients with
breast cancer. Expert Rev Anticancer Ther. 2003 Apr;3(2):193-201.
Review. PubMed PMID: 12722879.
359: Zapatero A, Martín de Vidales C, Pérez-Torrubia A. [Present and
future of adjuvant hormone therapy in breast cancer: clinical evidence
and clinical trials]. Rev Clin Esp. 2003 Apr;203(4):202-6. Review.
Spanish. PubMed PMID: 12681206.
360: Vogel CL. Update on the current use of hormonals as therapy in
advanced breast cancer. Anticancer Drugs. 2003 Apr;14(4):265-73. Review.
PubMed PMID: 12679730.
361: Ligibel JA, Winer EP. The aromatase inhibitors as adjuvant therapy
for hormone receptor-positive breast cancer. J Natl Compr Canc Netw.
2003 Apr;1(2):215-21. Review. PubMed PMID: 19768880.
362: Visvanathan K, Davidson NE. Aromatase inhibitors as adjuvant
therapy in breast cancer. Oncology (Williston Park). 2003
Mar;17(3):335-42, 347; discussion
347-50, 354. Review. PubMed PMID: 12661266.
363: Schmid P, Possinger K. Interactions of antioestrogens and aromatase
inhibitors. Forum (Genova). 2002;12(1):45-59. Review. PubMed PMID:
12634910.
364: Update on ATAC. Eur J Cancer. 2003 Feb;39(3):269. PubMed PMID:
12632577.
365: Aumiller J. [Summit meeting of breast cancer experts--many new
ideas and practical progress. When the breast becomes malignant]. MMW
Fortschr Med. 2003 Jan 23;145(3-4):4-8. German. PubMed PMID: 12619224.
366: Jordan VC. Is tamoxifen the Rosetta stone for breast cancer? J Natl
Cancer Inst. 2003 Mar 5;95(5):338-40. Review. PubMed PMID: 12618491.
367: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):615-43. PubMed PMID:
12616707.
368: Miller WR, Jackson J. The therapeutic potential of aromatase
inhibitors. Expert Opin Investig Drugs. 2003 Mar;12(3):337-51. Review.
PubMed PMID: 12605559.
369: Coleman RE. Current and future status of adjuvant therapy for
breast cancer. Cancer. 2003 Feb 1;97(3 Suppl):880-6. Review. PubMed
PMID: 12548590.
370: Benson JR, Pitsinis V. Update on clinical role of tamoxifen. Curr
Opin Obstet Gynecol. 2003 Feb;15(1):13-23. Review. PubMed PMID:
12544497.
371: Morris C, Wakeling A. Fulvestrant ('Faslodex')--a new treatment
option for patients progressing on prior endocrine therapy. Endocr Relat
Cancer. 2002 Dec;9(4):267-76. Review. PubMed PMID: 12542403.
372: Vogel VG, Costantino JP, Wickerham DL, Cronin WM. National surgical
adjuvant breast and bowel project update: prevention trials and
endocrine therapy of ductal carcinoma in situ. Clin Cancer Res. 2003
Jan;9(1 Pt 2):495S-501S. Review.
PubMed PMID: 12538506.
373: Ingle JN. Adjuvant endocrine therapy in postmenopausal breast
cancer. Clin Cancer Res. 2003 Jan;9(1 Pt 2):480S-5S. Review. PubMed
PMID: 12538504.
374: Ligibel JA, Winer EP. Clinical differences among the aromatase
inhibitors. Clin Cancer Res. 2003 Jan;9(1 Pt 2):473S-9S. Review. PubMed
PMID: 12538503.
375: Carlson RW. NCCN breast cancer clinical practice guidelines in
oncology: an
update. J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S61-3. PubMed PMID:
19795577.
376: Bross PF, Cohen MH, Williams GA, Pazdur R. FDA drug approval
summaries: fulvestrant. Oncologist. 2002;7(6):477-80. PubMed PMID:
12490735.
377: Thornton H. Questions about anastrozole for early breast cancer.
Lancet. 2002 Dec 7;360(9348):1890; author reply 1890-1. PubMed PMID:
12480405.
378: Stasi R, Terzoli E. Questions about anastrozole for early breast
cancer. Lancet. 2002 Dec 7;360(9348):1890; author reply 1890-1. PubMed
PMID: 12480404.
379: Jordan VC. A new day dawns: women without oestrogen or is a balance
best? Breast Cancer Res. 2002;4(6):218-21. Epub 2002 Sep 10. PubMed
PMID: 12473166; PubMed Central PMCID: PMC137939.
380: Baum M. Has tamoxifen had its day? Breast Cancer Res.
2002;4(6):213-7. Epub
2002 Aug 27. PubMed PMID: 12473165; PubMed Central PMCID: PMC137937.
381: Robertson JF. Current role of endocrine therapy in the management
of breast
cancer. Breast Cancer. 2002;9(4):276-81. PubMed PMID: 12459706.
382: Hozumi Y, Hakamata Y, Sasanuma H, Ogura S, Nagai H. Effects of
anastrozole on lipid metabolism compared with tamoxifen in rats. Breast
Cancer Res Treat. 2002 Nov;76(2):131-6. PubMed PMID: 12452450.
383: Mokbel K, Singh-Ranger G. Breast cancer chemoprevention--an update.
Curr Med Res Opin. 2002;18(6):329-31. Review. PubMed PMID: 12442878.
384: Gluck S. Anastrozole is superior to tamoxifen as first-line therapy
in hormone receptor-positive advanced breast carcinoma. Cancer. 2002 Dec
1;95(11):2442-3; author reply 2443-4. PubMed PMID: 12436453.
385: Wellington K, Faulds DM. Anastrozole: in early breast cancer.
Drugs. 2002;62(17):2483-90; discussion 2491-2. Review. PubMed PMID:
12421108.
386: Howell A. Selective oestrogen receptor downregulator. Eur J Cancer.
2002 Nov;38 Suppl 6:S61-2. PubMed PMID: 12409078.
387: Beat T. Anastrozole versus progestins/tamoxifen. Eur J Cancer. 2002
Nov;38 Suppl 6:S49-51. PubMed PMID: 12409073.
388: Bruntsch U. [Campaign against breast cancer. Are aromatase
inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)]. MMW
Fortschr Med. 2002 Sep
19;144(38):20. German. PubMed PMID: 12395697.
389: Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination)
adjuvant breast cancer trial in postmenopausal patients: factors
influencing the success of patient recruitment. Eur J Cancer. 2002
Oct;38(15):1984-6. PubMed PMID: 12376201.
390: Jones SE. A new estrogen receptor antagonist--an overview of
available data. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S19-21;
discussion S33-5. Review. PubMed PMID: 12353819.
391: Winquist E, Bramwell V, Vandenberg T. Anastrozole versus tamoxifen
as first-line therapy for advanced breast cancer: methodologic issues. J
Clin Oncol. 2002 Sep 1;20(17):3748-9; author reply 3749-50. PubMed PMID:
12202679.
392: Nabholtz JM, Reese D. Anastrozole in the management of breast
cancer. Expert Opin Pharmacother. 2002 Sep;3(9):1329-39. Review. PubMed
PMID: 12186625.
393: Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB,
Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA,
Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society
of Clinical Oncology technology assessment on the use of aromatase
inhibitors as adjuvant therapy for women with hormone receptor-positive
breast cancer: status report 2002. J Clin Oncol. 2002 Aug
1;20(15):3317-27. Review. PubMed PMID: 12149306.
394: Simon MS, Ibrahim D, Newman L, Stano M. Efficacy and economics of
hormonal therapies for advanced breast cancer. Drugs Aging.
2002;19(6):453-63. Review. PubMed PMID: 12149051.
395: Assikis VJ, Buzdar A. Recent advances in aromatase inhibitor
therapy for breast cancer. Semin Oncol. 2002 Jun;29(3 Suppl 11):120-8.
Review. PubMed PMID: 12138406.
396: Parker LM. Sequencing of hormonal therapy in postmenopausal women
with metastatic breast cancer. Clin Ther. 2002;24 Suppl C:C43-57.
Review. PubMed PMID: 12117075.
397: Cummings FJ. Evolving uses of hormonal agents for breast cancer
therapy. Clin Ther. 2002;24 Suppl C:C3-25. Review. PubMed PMID:
12117074.
398: Costantino J. The impact of hormonal treatments on quality of life
of patients with metastatic breast cancer. Clin Ther. 2002;24 Suppl
C:C26-42. Review. PubMed PMID: 12117073.
399: Brueggemeier RW. Aromatase inhibitors in breast cancer therapy.
Expert Rev Anticancer Ther. 2002 Apr;2(2):181-91. Review. PubMed PMID:
12113240.
400: Bundred N, Howell A. Fulvestrant (Faslodex): current status in the
therapy of breast cancer. Expert Rev Anticancer Ther. 2002
Apr;2(2):151-60. Review. PubMed PMID: 12113237.
401: Promising results for Arimidex and Femara. Expert Rev Anticancer
Ther. 2001
Dec;1(4):508-9. PubMed PMID: 12113080.
402: Dixon JM. Exemestane: a potent irreversible aromatase inactivator
and a promising advance in breast cancer treatment. Expert Rev
Anticancer Ther. 2002 Jun;2(3):267-75. Review. PubMed PMID: 12113050.
403: Köberle D, Thürlimann B. Anastrozole: pharmacological and clinical
profile in postmenopausal women with breast cancer. Expert Rev
Anticancer Ther. 2001 Aug;1(2):169-76. Review. PubMed PMID: 12113022.
404: Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res.
2002;4(4):133-6. Epub 2002 May 15. PubMed PMID: 12100736; PubMed Central
PMCID: PMC138731.
405: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials.
Methods Find Exp Clin Pharmacol. 2002 Apr;24(3):159-84. Review. PubMed
PMID: 12087878.
406: Dow KH. Existing and emerging endocrine therapies for breast
cancer. Cancer
Nurs. 2002 Apr;25 Suppl 2:6S-11S. Review. PubMed PMID: 12080538.
407: Lynn J. The oncology nurse's role in educating patients on
endocrine therapy for metastatic breast cancer--focus on fulvestrant.
Cancer Nurs. 2002 Apr;25 Suppl 2:12S-17S. PubMed PMID: 12080536.
408: Alba E, Ragonesi G, Colla F, Mazzoleni A, Farina C. [Antiestrogen
therapy in the treatment of breast neoplasms]. Minerva Ginecol. 2002
Jun;54(3):245-51. Review. Italian. PubMed PMID: 12063440.
409: Porpiglia M, Genta F, Vicelli R, De Nicola B, Ferraris F, Piccinno
R, Benedetto C. [The role of aromatase inhibitors in the treatment of
breast neoplasms. An evaluation of clinical efficacy and the
tolerability profile]. Minerva Ginecol. 2002 Apr;54(2):115-31. Review.
Italian. PubMed PMID: 12032450.
410: Jones SE. Antiaromatase agents: evolving role in adjuvant therapy.
Clin Breast Cancer. 2002 Apr;3(1):33-42. Review. PubMed PMID: 12020394.
411: Goss P. Anti-aromatase agents in the treatment and prevention of
breast cancer. Cancer Control. 2002 Mar-Apr;9(2 Suppl):2-8. Review.
PubMed PMID: 11965225.
412: Goss PE, Strasser K. Tamoxifen resistant and refractory breast
cancer: the value of aromatase inhibitors. Drugs. 2002;62(6):957-66.
Review. PubMed PMID: 11929341.
413: Nicholls H. Aromatase inhibitors continue their ATAC on tamoxifen.
Trends Mol Med. 2002;8(4 Suppl):S12-3. Review. PubMed PMID: 11927281.
414: Elkak AE, Mokbel K. Pure antiestrogens and breast cancer. Curr Med
Res Opin. 2001;17(4):282-9. Review. PubMed PMID: 11922402.
415: Howell A. Future use of selective estrogen receptor modulators and
aromatase inhibitors. Clin Cancer Res. 2001 Dec;7(12 Suppl):4402s-4410s;
discussion 4411s-4412s. Review. PubMed PMID: 11916232.
416: Goss PE. Preliminary data from ongoing adjuvant aromatase inhibitor
trials.
Clin Cancer Res. 2001 Dec;7(12 Suppl):4397s-4401s; discussion
4411s-4412s. Review. PubMed PMID: 11916231.
417: Howell A. Preliminary experience with pure antiestrogens. Clin
Cancer Res. 2001 Dec;7(12 Suppl):4369s-4375s; discussion 4411s-4412s.
Review. PubMed PMID: 11916227.
418: Johnson PE, Buzdar A. Are differences in the available aromatase
inhibitors
and inactivators significant? Clin Cancer Res. 2001 Dec;7(12 Suppl):4360s-4368s;
discussion 4411s-4412s. Review. PubMed PMID: 11916226.
419: Pritchard KI. The role of tamoxifen and aromatase inhibitors/inactivators
in postmenopausal patients. Clin Cancer Res. 2001 Dec;7(12 Suppl):4356s-4359s;
discussion 4411s-4412s. Review. PubMed PMID: 11916225.
420: Robertson JF. Estrogen receptor downregulators: new antihormonal
therapy for advanced breast cancer. Clin Ther. 2002;24 Suppl A:A17-30.
Review. PubMed PMID: 11911506.
421: Buzdar AU. Anastrozole (Arimidex)--an aromatase inhibitor for the
adjuvant setting? Br J Cancer. 2001 Nov;85 Suppl 2:6-10. Review. PubMed
PMID: 11900212; PubMed Central PMCID: PMC2375168.
422: Baum M. A vision for the future? Br J Cancer. 2001 Nov;85 Suppl
2:15-8. Review. PubMed PMID: 11900211; PubMed Central PMCID: PMC2375171.
423: Robertson JF. ICI 182,780 (Fulvestrant)--the first oestrogen
receptor down-regulator--current clinical data. Br J Cancer. 2001 Nov;85
Suppl 2:11-4. Review. PubMed PMID: 11900210; PubMed Central PMCID:
PMC2375169.
424: Sledge GW Jr. Hormones 'R' us. Clin Breast Cancer. 2002
Jan;2(4):251. PubMed PMID: 11899355.
425: Junker A, Wiedemann GJ, Possinger K. [Aromatase inhibitors of the
3rd generation. What can the "pill against breast cancer" really do?].
MMW Fortschr Med. 2002 Jan 31;144(5):46-8. German. PubMed PMID:
11883037.
426: Brodie A. Aromatase inhibitors in breast cancer. Trends Endocrinol
Metab. 2002 Mar;13(2):61-5. PubMed PMID: 11854020.
427: Howell A, Howell SJ, Clarke R, Anderson E. Where do selective
estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now
fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol.
2001 Dec;79(1-5):227-37. Review. PubMed PMID: 11850229.
428: Robertson JF. Faslodex (ICI 182, 780), a novel estrogen receptor
downregulator--future possibilities in breast cancer. J Steroid Biochem
Mol Biol. 2001 Dec;79(1-5):209-12. Review. PubMed PMID: 11850227.
429: Ragaz J. Adjuvant trials of aromatase inhibitors: determining the
future landscape of adjuvant endocrine therapy. J Steroid Biochem Mol
Biol. 2001 Dec;79(1-5):133-41. Review. PubMed PMID: 11850217.
430: Buzdar AU. A summary of second-line randomized studies of aromatase
inhibitors. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):109-14. Review.
PubMed PMID: 11850214.
431: World's largest breast cancer treatment trial supports anastrozole
use. Oncology (Williston Park). 2002 Jan;16(1):63. PubMed PMID:
11831610.
432: Cheung KL, Robertson JF. Fulvestrant. Expert Opin Investig Drugs.
2002 Feb;11(2):303-8. Review. PubMed PMID: 11829719.
433: Carlini P, Frassoldati A, De Marco S, Casali A, Ruggeri EM, Nardi
M, Papaldo P, Fabi A, Paoloni F, Cognetti F. Formestane, a steroidal
aromatase inhibitor after failure of non-steroidal aromatase inhibitors
(anastrozole and letrozole):
is a clinical benefit still achievable? Ann Oncol. 2001
Nov;12(11):1539-43. PubMed PMID: 11822752.
434: Munster PN, Horton J. Tamoxifen vs the aromatase inhibitors: news
from San Antonio, 2001. Cancer Control. 2001 Nov-Dec;8(6):478-9. PubMed
PMID: 11807416.
435: Toi M, Bando H, Saji S. Aromatase and aromatase inhibitors. Breast
Cancer. 2001;8(4):329-32. Review. PubMed PMID: 11791126.
436: Nabholtz JM, Reese DM. Third-generation aromatase inhibitors in the
treatment of advanced breast cancer. Breast Cancer. 2001;8(4):305-9.
Review. PubMed PMID: 11791122.
437: Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B,
von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing
Committee; Investigators Committee Members. Anastrozole is superior to
tamoxifen as first-line therapy in
hormone receptor positive advanced breast carcinoma. Cancer. 2001 Nov
1;92(9):2247-58. PubMed PMID: 11745278.
438: Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon
M, Ebbs
S, Gui G, Sacks N, Smith I. HER-2 amplification impedes the
antiproliferative effects of hormone therapy in estrogen
receptor-positive primary breast cancer. Cancer Res. 2001 Dec
1;61(23):8452-8. PubMed PMID: 11731427.
439: Exemestane: new preparation. No tangible advance in metastatic
breast cancer after tamoxifen failure. Prescrire Int. 2001
Aug;10(54):108-9. PubMed PMID: 11718178.
440: Anastrozole: licence extension. No advantage over tamoxifen in
advanced-stage breast cancer. Prescrire Int. 2001 Jun;10(53):76-7.
PubMed PMID: 11718168.
441: Murray R. Role of anti-aromatase agents in postmenopausal advanced
breast cancer. Cancer Chemother Pharmacol. 2001 Oct;48(4):259-65.
Review. PubMed PMID: 11710624.
442: Winer EP, Burstein HJ. New combinations with Herceptin in
metastatic breast
cancer. Oncology. 2001;61 Suppl 2:50-7. Review. PubMed PMID: 11694788.
443: Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors
in breast cancer. Oncology (Williston Park). 2001 Aug;15(8):965-72;
discussion 972,
977-9. Review. PubMed PMID: 11548977.
444: Longo F, Mansueto G. [Evolvement of hormone therapy for breast
cancer. Florence, March 14, 2001]. Tumori. 2001 May-Jun;87(3):A6-14.
Italian. PubMed PMID: 11505951.
445: Dowsett M, Cuzick J, Howell A, Jackson I; ATAC Trialists' Group.
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination,
during adjuvant endocrine therapy for early breast cancer in
postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen
alone or in combination' (ATAC) trial. Br J Cancer. 2001 Aug
3;85(3):317-24. PubMed PMID: 11487258; PubMed Central PMCID: PMC2364083.
446: Tominaga T. [Developments of hormonal agents for breast cancer].
Gan To Kagaku Ryoho. 2001 Jul;28(7):892-901. Review. Japanese. PubMed
PMID: 11478137.
447: Buzdar AU. Endocrine therapy in the treatment of metastatic breast
cancer. Semin Oncol. 2001 Jun;28(3):291-304. Review. PubMed PMID:
11402439.
448: Curran M, Wiseman L. Fulvestrant. Drugs. 2001;61(6):807-13;
discussion 814.
Review. PubMed PMID: 11398912.
449: Ingle JN. Aromatase inhibition and antiestrogen therapy in early
breast cancer treatment and chemoprevention. Oncology (Williston Park).
2001 May;15(5 Suppl 7):28-34. Review. PubMed PMID: 11396362.
450: Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR.
Intracellular aromatase and its relevance to the pharmacological
efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001
Jan-Mar;76(1-5):199-202. PubMed PMID: 11384878.
451: Semiglazov VP. [Modern approaches to hormone therapy of breast
cancer as a reflection of pathogenesis of the disease]. Vopr Onkol.
2001;47(2):195-9. Russian. PubMed PMID: 11383456.
452: Tsukagoshi S. [Development of a novel aromatase inhibitor,
anastrozole (Arimidex)--its basic and clinical studies]. Gan To Kagaku
Ryoho. 2001 Apr;28(4):549-60. Review. Japanese. PubMed PMID: 11329794.
453: Longo F. [National Conference of Medical Oncology. Controversies in
the treatment of breast cancer. Genova, October 28, 2000]. Tumori. 2000
Nov-Dec;86(6):A13-8. Italian. PubMed PMID: 11271674.
454: Mokbel K. The Twenty-third Annual San Antonio Breast Cancer
Symposium. Curr
Med Res Opin. 2001;16(4):276-84. PubMed PMID: 11268712.
455: Kerbrat P, Lefeuvre C. [Aromatase inhibitors: a review of clinical
trials].
Bull Cancer. 2000 Dec;87 Spec No:31-39. Review. French. PubMed PMID:
11250606.
456: Goss PE, Strasser K. Aromatase inhibitors in the treatment and
prevention of breast cancer. J Clin Oncol. 2001 Feb 1;19(3):881-94.
Review. PubMed PMID: 11157042.
457: Tobias JS, Baum M, Thornton H. Clinical trials in cancer: what
makes for a successful study? Ann Oncol. 2000 Nov;11(11):1371-3. PubMed
PMID: 11142473.
458: Messori A, Cattel F, Trippoli S, Vaiani M. Survival in patients
with metastatic breast cancer: analysis of randomized studies comparing
oral aromatase inhibitors versus megestrol. Anticancer Drugs. 2000
Oct;11(9):701-6. PubMed PMID: 11129731.
459: Howell A. Clarification of anastrozole/megestrol acetate trial
program design. J Clin Oncol. 2000 Dec 15;18(24):4109. PubMed PMID:
11118472.
460: Buzdar A. An overview of the use of non-steroidal aromatase
inhibitors in the treatment of breast cancer. Eur J Cancer. 2000 Sep;36
Suppl 4:S82-4. PubMed PMID: 11056331.
461: Dranitsaris G, Leung P, Mather J, Oza A. Cost-utility analysis of
second-line hormonal therapy in advanced breast cancer: a comparison of
two aromatase inhibitors to megestrol acetate. Anticancer Drugs. 2000
Aug;11(7):591-601. PubMed PMID: 11036964.
462: Crucitta E, Lorusso V, Attolico M, Sambiasi D, Mazzei A, De Lena M.
New aromatase inhibitors in the treatment of advanced breast cancer. Int
J Oncol. 2000 Nov;17(5):1037-41. Review. PubMed PMID: 11029510.
463: Sonoo H. [Aromatase inhibitors for treatment of advanced breast
cancers]. Nippon Rinsho. 2000 Apr;58 Suppl:322-7. Review. Japanese.
PubMed PMID: 11026013.
464: Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex):
development of a novel, "pure" antiestrogen. Cancer. 2000 Aug
15;89(4):817-25. Erratum in: Cancer 2001 Jan 15;91(2):455. PubMed PMID:
10951345.
465: Ikeda T, Masamura S, Matsui A, Hohjoh T, Kawaguchi M, Takayama S,
Tokura H,
Mitsui Y, Fujiwara K, Kitajima M. [Chemo/endocrine therapy for breast
cancer patients]. Gan To Kagaku Ryoho. 2000 Jul;27(8):1225-32. Review.
Japanese. PubMed
PMID: 10945021.
466: [In Europe Anastrozole approved for first-line treatment of
advanced breast
cancer in postmenopausal patients]. Tumori. 2000 May-Jun;86(3):A3.
Italian. PubMed PMID: 10939612.
467: Santen RJ, Harvey HA. Use of aromatase inhibitors in breast
carcinoma. Endocr Relat Cancer. 1999 Mar;6(1):75-92. Review. PubMed
PMID: 10732791.
468: Smith IE. Aromatase inhibitors: a dose-response effect? Endocr
Relat Cancer. 1999 Jun;6(2):245-9. Review. PubMed PMID: 10731116.
469: Baum M. Use of aromatase inhibitors in the adjuvant treatment of
breast cancer. Endocr Relat Cancer. 1999 Jun;6(2):231-4. Review. PubMed
PMID: 10731114.
470: Dixon JM, Love CD, Renshaw L, Bellamy C, Cameron DA, Miller WR,
Leonard RC.
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Endocr Relat Cancer. 1999 Jun;6(2):227-30. Review. PubMed PMID:
10731113.
471: Buzdar AU. Role of aromatase inhibitors in advanced breast cancer.
Endocr Relat Cancer. 1999 Jun;6(2):219-25. Review. PubMed PMID:
10731112.
472: Buzdar AU. Critique of survival update analysis from two phase III
anastrozole clinical trials. Ann Surg Oncol. 1999 Dec;6(8 Suppl):8S-11S.
PubMed PMID: 10619453.
473: Bajetta E, Zilembo N, Bichisao E. Aromatase inhibitors in the
treatment of postmenopausal breast cancer. Drugs Aging. 1999
Oct;15(4):271-83. Review. PubMed
PMID: 10582774.
474: Yao JC, Thomakos N, McLaughlin P, Buchholz TA, Kudelka AP.
Tamoxifen-induced thrombocytopenia. Am J Clin Oncol. 1999
Oct;22(5):529-32. Review. PubMed PMID: 10521073.
475: Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors
in postmenopausal breast cancer. Drug Saf. 1999 Oct;21(4):297-309.
Review. PubMed PMID: 10514021.
476: Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment
of quality of life in women undergoing hormonal therapy for breast
cancer: validation of an endocrine symptom subscale for the FACT-B.
Breast Cancer Res Treat. 1999 May;55(2):189-99. PubMed PMID: 10481946.
477: de Jong PC, Blijham GH. New aromatase inhibitors for the treatment
of advanced breast cancer in postmenopausal women. Neth J Med. 1999
Aug;55(2):50-8.
Review. PubMed PMID: 10474272.
478: Njar VC, Brodie AM. Comprehensive pharmacology and clinical
efficacy of aromatase inhibitors. Drugs. 1999 Aug;58(2):233-55. Review.
PubMed PMID: 10473018.
479: Hamilton A, Piccart M. The third-generation non-steroidal aromatase
inhibitors: a review of their clinical benefits in the second-line
hormonal treatment of advanced breast cancer. Ann Oncol. 1999
Apr;10(4):377-84. Review. PubMed PMID: 10370778.
480: Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Pacini P, Gallo L,
Sismondi P, Giai M, Genta F, Mustacchi G, Agostara B, Bolognesi A, Villa
E, Schieppati G, Ausili Cefaro GP, Bellantone R, Farris A, Sassi M,
Patrone F. Italian Breast Cancer Adjuvant Chemo-Hormone Therapy
Cooperative Group Trials. GROCTA Trials. Recent Results Cancer Res.
1998;152:453-70. Review. PubMed PMID: 9928580.
481: Espie M. [Breast cancer: new therapeutic strategies]. Presse Med.
1998 Dec 12;27(39):2049-54. French. PubMed PMID: 9893697.
482: Lamb HM, Adkins JC. Letrozole. A review of its use in
postmenopausal women with advanced breast cancer. Drugs. 1998
Dec;56(6):1125-40. Review. PubMed PMID:
9878997.
483: Wiseman LR, Adkins JC. Anastrozole. A review of its use in the
management of postmenopausal women with advanced breast cancer. Drugs
Aging. 1998 Oct;13(4):321-32. Review. PubMed PMID: 9805213.
484: Lřnning PE, Geisler J, Dowsett M. Pharmacological and clinical
profile of anastrozole. Breast Cancer Res Treat. 1998;49 Suppl 1:S53-7;
discussion S73-7. Review. PubMed PMID: 9797018.
485: Dowsett M. Theoretical considerations for the ideal aromatase
inhibitor. Breast Cancer Res Treat. 1998;49 Suppl 1:S39-44; discussion
S73-7. Review. PubMed PMID: 9797016.
486: Lřnning PE. Aromatase inhibitors and their future role in
post-menopausal women with early breast cancer. Br J Cancer. 1998 Sep;78
Suppl 4:12-5. PubMed PMID: 9741783; PubMed Central PMCID: PMC2062757.
487: Baum M. Tamoxifen--the treatment of choice. Why look for
alternatives? Br J
Cancer. 1998 Sep;78 Suppl 4:1-4. PubMed PMID: 9741780; PubMed Central
PMCID: PMC2062753.
488: Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL,
Eiermann W,
Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol
acetate in the treatment of postmenopausal women with advanced breast
carcinoma: results of
a survival update based on a combined analysis of data from two mature
phase III
trials. Arimidex Study Group. Cancer. 1998 Sep 15;83(6):1142-52. Erratum
in: Cancer 1999 Feb 15;85(4):1010. PubMed PMID: 9740079.
489: Hortobagyi GN, Buzdar AU. Anastrozole (Arimidex), a new aromatase
inhibitor
for advanced breast cancer: mechanism of action and role in management.
Cancer Invest. 1998;16(6):385-90. Review. PubMed PMID: 9679529.
490: Friedrichs K, Jänicke F. [Aromatase inhibitors--new possibilities
in treatment of breast carcinoma]. Praxis (Bern 1994). 1998 Apr
22;87(17):584-8. Review. German. PubMed PMID: 9623325.
491: Harvey HA. Emerging role of aromatase inhibitors in the treatment
of breast
cancer. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):32-5. Review.
PubMed PMID: 9556789.
492: Buzdar AU. Anastrozole: a new addition to the armamentarium against
advanced breast cancer. Am J Clin Oncol. 1998 Apr;21(2):161-6. Review.
PubMed PMID: 9537204.
493: Higa GM, alKhouri N. Anastrozole: a selective aromatase inhibitor
for the treatment of breast cancer. Am J Health Syst Pharm. 1998 Mar
1;55(5):445-52. Review. PubMed PMID: 9522927.
494: Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell
JA, Hawk ET, Boone CW, Sigman CC. Aromatase inhibitors as potential
cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1998
Jan;7(1):65-78. Review.
PubMed PMID: 9456245.
495: [ECCO 9 -- Future trends in endocrine therapy of breast cancer].
Tumori. 1997 Sep-Oct;83(5):874-6. Italian. PubMed PMID: 9446251.
496: Roseman BJ, Buzdar AU, Singletary SE. Use of aromatase inhibitors
in postmenopausal women with advanced breast cancer. J Surg Oncol. 1997
Nov;66(3):215-20. Review. PubMed PMID: 9369969.
497: Harvey HA. Issues concerning the role of chemotherapy and hormonal
therapy of bone metastases from breast carcinoma. Cancer. 1997 Oct
15;80(8 Suppl):1646-51. Review. PubMed PMID: 9362431.
498: Wiseman LR, Spencer CM. Vorozole. Drugs Aging. 1997
Sep;11(3):245-50; discussion 251-2. Review. PubMed PMID: 9303282.
499: Dowsett M. Aromatase inhibitors come of age. Ann Oncol. 1997
Jul;8(7):631-2. PubMed PMID: 9296213.
500: New aromatase inhibitors for breast cancer. Drug Ther Bull. 1997
Jul;35(7):55-6. Review. PubMed PMID: 9282426.
501: Buzdar AU, Jonat W, Howell A, Plourde PV. ARIMIDEX: a potent and
selective aromatase inhibitor for the treatment of advanced breast
cancer. J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):145-9. Review.
PubMed PMID: 9365184.
502: Blamey RW. The role of selective non-steroidal aromatase inhibitors
in future treatment strategies. Oncology. 1997;54 Suppl 2:27-31. Review.
PubMed PMID: 9394858.
503: Jonat W. Clinical overview of anastrozole--a new selective oral
aromatase inhibitor. Oncology. 1997;54 Suppl 2:15-8. Review. PubMed
PMID: 9394855.
504: Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL,
Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a
potent and selective aromatase inhibitor, versus megestrol acetate in
postmenopausal women with advanced breast cancer: results of overview
analysis of two phase III trials. Arimidex Study Group. J Clin Oncol.
1996 Jul;14(7):2000-11. PubMed PMID: 8683230.
505: Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective
fourth-generation aromatase inhibitor. Breast Cancer Res Treat.
1994;30(1):103-11. PubMed PMID: 7949201.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
